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Abstract
Loss of immunoregulation in the intestine results in inflammation, such as is observed in
the chronic, relapsing, inflammatory bowel diseases (IBD), Crohn's disease and
ulcerative colitis. However, our understanding of this process remains incomplete. The
cytokine granulocyte-colony stimulating factor (G-CSF) is an important stimulator of
granulopoiesis in steady-state and during inflammation, but has also been shown to have
anti-inflammatory effects and is a potential therapeutic for IBD. In addition, certain
strains of bacteria, termed probiotics, have been postulated to have anti-inflammatory
effects in the intestine. The mechanisms by which these strains of bacteria elicit antiinflammatory effects are not fully understood.
In this thesis, I show that G-CSF plays an important anti-inflammatory role in the
response to the probiotic bacterial strain Lactobacillus rhamnosus GR-1 (GR-1) and
within the intestinal immune system. Macrophages treated with GR-1 produce high
amounts of G-CSF, but low amounts of tumor necrosis factor (TNF)α and interleukin
(IL)-12. G-CSF produced by GR-1-treated macrophages inhibits the activation of c-Jun
N-terminal Kinase as well as the production of TNFα and IL-12 by macrophages and
dendritic cells (DCs), respectively. Human intestinal lamina propria mononuclear cells
(LPMCs) released high levels of G-CSF when cultured ex vivo, which was reduced in
LPMCs of IBD patients. Non-IBD LPMCs produced higher G-CSF after stimulation with
GR-1 than with E. coli, while IBD LPMCs showed the opposite pattern. The release of
G-CSF by mouse intestinal tissue samples was dependent upon MyD88 signaling, but
independent of the intestinal microbiota. G-CSFR-/- intestinal tissues express higher
levels of the cytokines IL-12, IL-23, and TNFα, suggesting that G-CSF inhibits
inflammatory cytokine production in the gut. G-CSFR-/- mice show increased weight
loss and intestinal tissue damage in an acute colitis model induced by dextran sulfate
sodium (DSS), and developed a pseudomembranous structure associated with clusters of
bacteria over regions of severely damaged colon. Increased levels of intestinal IL-17 are
seen in DSS-treated G-CSFR-/- mice, indicating that G-CSF may play a role in regulating
the production of IL-17 in the intestine. Overall, I have shown that the
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immunomodulatory properties of G-CSF are important in intestinal immunoregulation,
the effects of probiotics, and IBD.
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1.1 OVERVIEW
The immune system is a collection of cells and tissues in the body that function to
respond to and eliminate certain threats to the health of the host, encompassing
pathogenic organisms, foreign substances, and abnormal tissues or cells such as those that
have undergone cancerous transformation. This is achieved through a set of powerful
effector mechanisms, which while important for host protection, can have damaging
collateral effects on healthy host tissues if activated in excess. The intestinal immune
system must remain tolerant to the multitude of commensal organisms present in the gut,
yet responsive to invading pathogens (1). Any breakdown in this balance can have severe
consequences, as evidenced by the inflammatory bowel diseases (IBD). IBD consists of
two distinct forms, Crohn’s disease and ulcerative colitis, although considerable
variability exists in the array of symptoms that may be present in an individual patient.
The etiology of these diseases is unknown, but it is thought to involve a complex
interplay between environmental factors, such as the intestinal microbiota, and aberrant
innate and adaptive immune responses, ultimately resulting in a loss of immunological
regulation and extensive intestinal tissue damage. Immunological homeostasis in the
intestine involves both the innate sensing of microbes and the presence of
immunoregulatory cytokines (2). The role of cytokines in IBD has generated much
research interest due to their potential use as drugs or drug targets. The cytokine
granulocyte colony-stimulating factor (G-CSF) is primarily known as an important
regulator of the development and effector function of granulocytes, but also has
immunoregulatory effects on other immune cells (3, 4). G-CSF may be beneficial in
ameliorating intestinal inflammation, as indicated in both animal models of colitis and
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clinical trials for IBD (5). In addition to immunoregulatory cytokines, the intestinal
microbiota may exert a positive effect on the maintenance of intestinal immunological
homeostasis. Strains of probiotic bacteria, which may have anti-inflammatory properties,
have been postulated to be beneficial in IBD. We have previously found that a probiotic
strain of Lactobacillus highly upregulates the production of G-CSF in macrophages in
vitro (6), suggesting that G-CSF may play an important role in the effects of probiotics
and in intestinal immunoregulation. Therefore, the aim of this thesis was to explore the
role of G-CSF in the intestine and the anti-inflammatory effects of probiotics.

1.2 THE IMMUNE SYSTEM
The immune system represents a key component of the body that functions to protect the
host from pathogenic organisms and to eliminate abnormal cells. The importance of the
immune system has been highlighted by the discovery of multiple types of
immunodeficiency, which typically result in increased susceptibility to infection (7).
Equally important has been the discovery of inflammatory and autoimmune diseases,
which result from an inappropriate activation of the immune system against innocuous
substances or the host’s own tissue (8). Therefore, the immune system represents a
double-edged sword: an adaptation that has allowed survival despite the ubiquitous
presence of potentially pathogenic microbes, yet one with the potential to severely
damage the host if not tightly controlled.
Conceptually, the vertebrate immune system is often grouped into the “innate” and
“adaptive” arms. The innate immune system is generally thought of as those components
that rely upon only germline-encoded genetic information for their function (9). Many
aspects of these components are evolutionarily ancient and shared by diverse forms of
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multicellular life (10). The hallmark of the innate immune system is the rapid response to
infection, even to pathogens never encountered before. The adaptive immune system is
characterized by the ability to respond to a repeated exposure with increasingly
effectiveness and specificity towards structures, known as antigens, associated with the
microbe or substance eliciting the response (11). The adaptive immune system is more
evolutionarily recent, and is generally found in jawed vertebrates. Although some
specific examples, such as natural killer and γδ T cells, blur these distinctions between
innate and adaptive immunity, these rough conceptual categories aid in the understanding
of the immune system (12-14). The components of the innate and adaptive immune
systems are interdependent, relying upon each other for the proper functioning of the
whole system (15, 16). The cells of the immune system communicate with each other
through cell membrane-associated molecules and the production of cytokines,
chemokines, and other soluble mediators that orchestrate the immune response.

1.3 CYTOKINES
Cells of the immune system depend on intercellular communication for the effective
orchestration of the immune response. One aspect of this communication is through the
production of secreted messenger proteins called cytokines. Numerous cytokines have
been discovered, and the functions each cytokine in the immune system may be unique or
overlapping with other cytokines. In addition, individual cytokines often have multiple
biological effects. Cytokines include: the families of proteins known as interleukins (IL),
produced by immune cells and other cells and which act upon immune cells; chemokines,
which are known for their ability to regulate the chemotaxis of cells; and growth factors,
which stimulate the development of different cell lineages. The effects of a cytokine can

5

differ depending upon the target cell, and different combinations of cytokines can have
different effects than each cytokine individually, making the network of potential
communications through cytokines highly complex (17). These proteins represent
important therapeutic targets, as levels can be readily manipulated by the administration
of pure cytokine produced by recombinant technology, or by the administration of
cytokine-neutralizing or receptor-blocking antibodies to block their activity in vivo.
However, great care must be taken in manipulating cytokines due to the complexity of
the cytokine network, and, despite years of research, new functions are still being
ascribed to known and newly discovered cytokines.

1.4 INNATE IMMUNITY
Innate immunity includes physical and chemical barriers, soluble factors, and specialized
cell types. Physical barriers such as the skin and mucosal epithelial layers, prevent
microbial access to host tissues. Secreted factors including anti-microbial peptides are
released at mucosal surfaces by specialized cells (e.g. paneth cells), and can destroy
bacteria before they have the chance to cross the epithelial barrier (18). The complement
system can function independently or in concert with products of adaptive immunity to
cause the lysis or opsonization of pathogenic microbes (19). Effector cells such as
macrophages and neutrophils recognize, ingest, and destroy foreign bodies, and produce
cytokines and chemokines that direct further immune responses. Certain “non-immune”
cells such as epithelial cells and fibroblasts also participate in innate immunity as these
cells can also recognize foreign microbes and produce cytokines and chemokines (20,
21). In organisms possessing adaptive immune components, a key function of the innate
immune system is also the activation and regulation of the adaptive immune system.
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1.4.1

Pattern-recognition receptors

Over 20 years ago Charles Janeway proposed that the innate immune system must
possess a set of non-clonally distributed receptors capable of recognizing conserved
structures of foreign pathogens, as a mechanism that allows the immune system to
distinguish host-derived antigens (self) from foreign antigens (non-self) (22). The
following years witnessed the confirmation of this idea, with the discovery of a class of
proteins known as pattern-recognition receptors (23). These receptors include the toll-like
receptors (TLRs) (24), C-type lectin receptors (CLRs) such as Dectin-1 (25, 26), the
nucleotide-binding domain and leucine-rich repeat containing proteins (NLRs) (27), and
the retinoic acid-inducible gene I-like receptors (RLRs) (28), each of which is a family of
proteins capable of detecting pathogen-associated molecular patterns or self molecules
associated with tissue inflammation and damage.
TLRs are associated with either the plasma or endosomal membranes and recognize the
products of parasites, bacteria and viruses. Two of the most well studied TLRs are TLRs
4 and 2, which can recognize components of Gram-negative and Gram-positive bacteria,
respectively (29, 30). Stimulation of TLRs by bacterial ligands results in nuclear factor
(NF)-κB and mitogen activated protein kinase (MAPK) activation, resulting in the
transcription of a multitude of anti-microbial proteins and inflammatory genes (31).
Activation of dendritic cells through TLRs also leads to the upregulation of the
expression of various cytokines and co-stimulatory molecules that play important roles in
the activation of adaptive immunity (32). C-type lectin receptors bind carbohydrate
structures associated with microbes, and can activate intracellular signalling pathways on
their own or modulate signalling pathways activated by TLRs, as well as mediate the
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internalization of the recognized structures for antigen processing and presentation (33).
In contrast to the TLRs and CLRs, NLRs and RLRs recognize ligands in the cytoplasm
(27, 28). RLRs are known to recognize double-stranded RNAs associated with RNA
viruses, while NLRs are stimulated by diverse stimuli, ranging from bacterial and viral
components, to non-microbial compounds such as uric acid crystals and asbestos.

1.4.2
1.4.2.1

Cells of the innate immune system
Monocytes, macrophages, and dendritic cells

Monocytes, macrophages and dendritic cells (DCs) are highly heterogeneous and
functionally diverse cells that process information from the tissue environment, including
cytokines, tissue damage-related factors, and other inflammatory stimuli, and produce an
array of cytokines and cell surface factors that are thought to instruct the behavior of the
adaptive immune system (34). Monocytes, macrophages and DCs are functionally and
developmentally related, and the distinction between macrophages and DCs is often
blurry. Indeed, it has been argued that such a distinction is artificial (35). Functionally,
while macrophages are considered tissue resident, DCs are typically thought of as
migratory, capturing antigens in the peripheral tissues and migrating to the secondary
lymphoid organs where they can present the antigens to T cells. In this model,
macrophages serve as bactericidal effectors, cytokine producers, and amplifiers of local T
cell responses, while DCs are the key antigen presenting cells (APCs) important for
activation of naïve T cell responses to a never-before-encountered antigen. Multiple
different subsets of monocytes, macrophages, and DCs have been described, each with
different characteristics, and are delineated based on their morphology, tissue localization
or cell surface marker expression (36).
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1.4.2.2

Granulocytes

Granulocytes, such as neutrophils, basophils, and eosinophils, are important effector cells
in the immune response. Neutrophils serve an important function in host defense, and the
reduced presence of neutrophils in the peripheral blood (neutropenia) is often
accompanied by opportunistic infections (37). Neutrophils may also contribute to tissue
damage during chronic inflammation, as seen in rheumatoid arthritis, through their
release of toxic mediators such as reactive oxygen and nitrogen species (38). Therefore,
neutrophil production is tightly regulated (39). The initiation of inflammation causes a
rapid increase in the circulating levels of neutrophils, which then migrate to the tissues
and defend against infection. Because these cells are very short lived, when the
inflammatory stimulus is resolved (ie the infection is cleared), the numbers of neutrophils
quickly return to normal. Basophils and eosinophils are specialized granulocytes that play
an important role in the defense against parasitic infection, but can also play a pathogenic
role in allergic responses (40).

1.4.3

Cross-talk between innate immune cells

Innate immune cells can affect each other’s function through a variety of means.
Macrophages in particular can produce a multitude of cytokines and chemokines that can
coordinate the activities of other cells during an inflammatory response. Epithelial and
endothelial cells can release soluble mediators important for inflammation as well the
maintenance of immune homeostasis during non-inflamed conditions (21). In addition to
soluble mediators, direct cellular interactions can affect innate immune cell function. For
example, phagocytosis of non-infected, non-activated, apoptotic neutrophils by
macrophages and DCs can have strong anti-inflammatory effects, inhibiting subsequent
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IL-12 and IL-23 production (41, 42). Conversely, uptake of activated apoptotic
neutrophils by macrophages at the site of inflammation may enhance the anti-microbial
activity of the macrophage (43). Activated neutrophils can also activate DCs through the
interaction of Mac-1 on the surface of neutrophils with DC-Sign on the surface of DCs,
and through the production of tumor necrosis factor (TNF)α (44).

1.5 ADAPTIVE IMMUNITY
Adaptive immunity encompasses the elements of the immune response capable of
specifically binding to antigenic structures using receptors whose sequence is varied
through an elegant system of DNA recombination and rearrangement, generating protein
structures which can bear binding complementarity to antigens that have yet to be
encountered (45). These structures are incorporated as variable regions on the membranebound and secreted antibodies of B cells and the T cell receptor of T cells. Each
individual T or B cell will then express a single type of receptor structure, but since the
recombination is random, the entire pool of cells contains a large diversity of receptor
specificities. Once a B or T cell encounters an antigenic epitope with complementarity to
the structure of its variable region, together with the appropriate activation signals from
the innate immune system, the cell will undergo proliferation, enriching the pool of cells
specific for the original antigen (16, 46). This process is known as clonal expansion. This
enrichment leads to the increased presence of effector cells able to eliminate the foreign
microbe, as well as the formation of long-lived “memory” cells, that can respond quickly
to subsequent infection with the same pathogen.
With the ability to recognize a tremendous repertoire of antigens through a system of
random genetic recombination also comes the potential to recognize “self”, which could
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be misinterpreted as “non-self”. These misinterpreted self-antigens, or cross-reactive
responses to self-antigens exhibiting similarity to foreign structures, can then drive an
immune attack on the host’s own tissues (auto-immune disease). Although the immune
system protects against self reactivity through deleting self-reactive clones during
development (termed “central tolerance”), and through controlling self-reactive clones in
the periphery (peripheral tolerance), this type of attack on self tissues can occur, with
devastating effects.

1.5.1

The T helper subset concept

T cells in the periphery can be divided into cluster of differentiation (CD)4+ and CD8+
subsets; CD4+ T helper (Th) cells serve to activate other cells of the immune system such
as macrophages and B cells, while CD8+ cells possess cytotoxic activity that, for
example, leads to the recognition and destruction of virally infected cells. Early work
using clonal populations of CD4+ T cells in vitro identified the existence of two distinct
populations: one characterized by the ability to produce high levels of interferon (IFN)γ
and TNFα, and another capable of producing high levels of IL-4 (47). The paradigm of
these two subsets of CD4+ Th cells, denoted as Th1 and Th2 cells, respectively, has
become a key concept in the operation of T cell mediated immunity. It is thought that
Th1 cells are required for the protection against intracellular pathogens, by activating
macrophages and cytotoxic CD8+ T cells. In contrast, the Th2 subset plays a role in the
protection against helminth infection. These subsets can have different roles in immune
mediated disease; Th1 is often associated with chronic inflammatory diseases, whereas
Th2 can promote the development of allergic responses. Typically, CD4+ T cells are
defined as members of these subsets based on the profile of cytokines they produce and
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the presence of lineage defining transcription factors: T-box expressed in T cells (T-bet)
for the Th1 lineage and GATA-binding protein 3 (GATA-3) for the Th2 lineage (48, 49).
While the Th1/Th2 paradigm provides a useful framework for understanding the function
of the adaptive immune response, care must be taken not to over-generalize this
dichotomy, as mixed responses are often seen in vivo (50, 51).
Recently, the Th1/Th2 paradigm has been expanded to include the newly discovered
Th17 and T follicular helper (Tfh) subsets (52, 53). Th17 cells have been identified as
CD4+ T cells capable of producing large amounts of the cytokine IL-17. These cells are
also known to express the transcription factor retinoic acid receptor (RAR)-related
orphan receptor γ T (RORγT), which directs their differentiation (54). These cells
initially develop in the presence of transforming growth factor (TGF)-β and IL-6, and the
IL-12-related cytokine IL-23 is important for their continued differentiation (55, 56);
however, recent evidence has shown a TGF-β-independent mode of Th17 generation,
requiring IL-23, IL-6, and IL-1β (57). IL-17 is an important regulator of neutrophil
homeostasis by inducing the production of G-CSF (42, 58, 59). Th17 cells are thought to
play a largely pro-inflammatory role, which can be protective in the case of fungal
infections but pathogenic in certain autoimmune diseases such as multiple sclerosis. The
Tfh subset secretes high levels of IL-21, and is specialized to provide help for the
development of antibody-secreting B cells in the lymphoid tissue. Interestingly, IL-12,
long thought of as a key Th1 cytokine, is important for the development of Tfh in
humans, but not mice (60).
In addition to these immune-activating subsets, a subset known as regulatory T cells
(Tregs) has been shown to play an important role in the inhibition of T cell responses.
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Tregs are important for the maintenance of self-tolerance by blocking activation of selfreactive T cells in the periphery (61, 62), and in the maintenance of tolerance to the
intestinal commensal microbiota (63). Tregs express the cytokines IL-10 and TGF-β, and
Treg lineage determination appears to rely on the transcription factor forkhead box P3
(Foxp3) (64-66). The Treg lineage itself consists of natural Tregs (nTregs), which
develop in the thymus, and induced Tregs (iTregs), which are derived from naïve CD4+
T cells that convert to a Treg phenotype in the periphery (67). nTregs tend to express T
cell receptors of higher affinity for self antigens, and therefore may mediate tolerance to
self antigens in a specific manner (68, 69). iTregs may be induced in the periphery
through several different mechanisms, and consist of several described subsets such as
the Foxp3- Tr1 cells that are induced by IL-10 (70), and the conversion of Foxp3- T cells
to Foxp3+ in the gut-associated lymphoid tissue via TGF-β and retinoic acid (71, 72).
TGF-β-producing Th3 cells are another regulatory T cell type and play an important role
in tolerance to orally administered antigens (73). As Tregs are important for the
regulation of chronic inflammatory or autoimmune diseases, they represent an important
therapeutic target.

1.5.2

Cross-talk between innate and adaptive immunity and
activation of the adaptive response

In the context of an organism possessing both innate and adaptive immunity, innate
immunity plays a key role in activating adaptive immunity, alerting it to the presence of a
foreign microbe and directing the appropriate adaptive response though the production of
cytokines and cell surface proteins that function to activate adaptive cells (16). A key
aspect of this activation is antigen presentation, in which broken-down components
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derived from the microbe or other factor to which immunity is going to be elicited
(antigens) are “presented” to adaptive immune cells on the cell surface. This occurs
through the loading of degraded products of the pathogenic organism onto glycoproteins
known as the major histocompatiblity complex (MHC) proteins (74). These proteins have
a binding surface in which the foreign antigen is loaded, after which the MHC:peptide
complex is trafficked to the cell surface where it can activate T cells. Certain cell types
are known as “professional” antigen-presenting cells (APC) because of their high
efficiency in the activation of adaptive immunity. B cells, macrophages, and dendritic
cells (DCs) in particular are professional APCs, with dendritic cells thought of as the only
type capable of activating naïve T cells, and therefore initiating responses to a foreign
antigen which the immune system has not previously encountered (75).
Before priming the adaptive response, DCs must be stimulated to produce the appropriate
co-stimulatory markers and cytokines to allow activation of T cells that recognize the
antigen presented on the MHCII molecule of the DC (76). Typically, signalling through
pattern recognition receptors such as the TLRs or NLRs can serve this function (32, 77).
Non-activated DCs are thought to exist in a “resting” or “immature” state, and show avid
phagocytic activity. Upon “activation” or “maturation”, dendritic cells show only very
low phagocytic activity, but upregulate the expression of co-stimulatory molecules, such
as CD80 and CD86. These proteins engage CD28 on the surface of T cells that bind
specifically to the MHC:peptide complex presented on the DC surface, which sends
proliferative and pro-survival signals to the T cell (78). In addition, activated DCs
produce cytokines that can also play a role in the T cell response. Presentation of antigen
without the activation of the DC can result in no response or tolerance towards that
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antigen; however, “activated” DCs may still be tolerogenic (79). This requirement for
activation though microbial or “danger” associated innate immune stimuli serves as a
safety mechanism to ensure that adaptive responses are only initiated when a true threat is
present, fulfilling Janeway’s proposal of innate immune control over self-non-self
discrimination (22). Additionally, the phenotype of the DC may be modulated by
cytokines present in the microenvironment, such as those produced by epithelial cells or
macrophages (80). DCs may also be able to selectively target T cells stimulated in the
lymph node to home to the tissue where the antigen was encountered by the DC, through
affecting the expression of various chemokine receptors on the responding T cells (81,
82). Therefore, the type of adaptive response initiated is controlled and localized by the
soluble and membrane-bound factors produced by the DC in response to stimuli
encountered during and before exposure to the antigen. In this model, the DC represents a
key point for the integration of information in the immune system (83). Extensive
research is being done on how to modify the functionality of DCs in order to control the
types of immune responses generated, such as through using different types of pattern
recognition receptor ligands as adjuvants during immunization or different cytokine
cocktails for the generation of DCs (84).
Once the adaptive immune response is activated, the cytokines produced by activated T
cells direct the effector functions of innate immune cells, such as macrophages and
granulocytes. IFNγ produced by Th1 cells can induce a “classical activation” phenotype
in macrophages, resulting in enhanced bactericidal activity (85). Th1-derived TNFα can
also enhance the maturation of DCs (76). Th2 cells produce IL-4 and IL-13, which can
induce an “alternative activation” phenotype in macrophages and contribute to the
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activation and recruitment of basophils (86). IL-17, produced by Th17 cells, can serve to
enhance the proinflammatory response and recruit neutrophils and monocytes to the
inflamed tissue by inducing the production of multiple chemokines and cytokines (87).

1.6 INTESTINAL IMMUNITY
Representing a vast interface between the immune system and the environment, the
intestine is an important site of immune activity in the body. The intestinal immune
system faces a special task: to prevent entry and damage caused by pathogenic microbes,
but at the same time avoid overt inflammation in response to the multitude of foreign
antigens and commensals in the intestinal lumen. It is not fully understood how this
immunological balance is achieved, but it is apparent that loss of this balance can have
dramatic pathological consequences.

1.6.1

The structure of the intestinal immune system

The intestinal microbiota represents a large pool of potential inflammatory stimuli, which
is separated from a dense network of intestinal macrophages and other immune cells
present in the intestinal lamina propria by only a thin layer of epithelial cells. These
microbes are prevented from breaching the mucosal barrier and inducing inflammatory
responses by several mechanisms (88). A thick mucus layer maintains some degree of
physical separation between bacteria and the epithelial layer and can inhibit pathogen
growth through acidic pH and the presence of enzymes such as lysozyme. Anti-microbial
peptides and immunoglobulins such as IgA and IgM are secreted into the luminal space,
preventing invasion of the tissue (89, 90). The epithelial layer itself serves as a barrier
that pathogens must circumvent in order to cause infection, and plays an active role in
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shaping the immune response induced in the intestine by modulating DC function (21,
91). In addition, a large population of macrophages lies in the lamina propria and can
respond to any breach of the epithelial barrier (92). Under normal conditions, these
macrophages have strong phagocytic and bactericidal activity, but are resistant to the
induction of inflammatory cytokine expression (93). Active sampling of the luminal
content occurs through specialized cells known as Microfold cells (94). Microfold cells
are located in the epithelium associated with lymphoid follicles, and transcytose antigens
and microbes from the lumen to be taken up by APCs. Adaptive immune cells, including
naïve T cells, can interact with antigen loaded APCs in the gut associated lymphoid tissue
(GALT), Peyer’s patches and isolated lymphoid follicles (95). At least some subsets of
DCs within the GALT imprint intestine-specific tissue homing upon activated T cells,
through a mechanism that involves retinoic acid (96, 97). These T cells may then respond
to antigens presented locally in the intestine. The cytokines and chemokines produced
can result in the influx of neutrophils and monocytes. This acute inflammation generally
results in the clearance of the pathogen; however, tissue damage resulting from this
response can cause the further influx of antigens and activation of the immune response,
thereby perpetuating the inflammation. To prevent this, the intestinal immune system
must be tightly regulated, so that inflammatory responses resolve instead of becoming
chronic.

1.6.2

The regulation of the intestinal immune system

Immunological homeostasis in the intestine involves a combination of defense systems
that prevent breaching of the mucosal barrier by intestinal microbes as described above,
and immunoregulatory mechanisms that prevent inflammatory responses to luminal
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antigens. Anti-inflammatory cytokines, including IL-10 and TGF-β, as well as the
regulatory functions of Tregs and DCs, play a role in the maintenance of intestinal
homeostasis and tolerance towards the commensal microbiota (98, 99). DCs continuously
migrate from the intestine to the mesenteric lymph nodes, where they present antigens
taken up in the intestinal tissue (100, 101). This process appears to be important for the
induction of tolerance to orally-ingested antigens (102). Intestinal macrophages may also
have anti-inflammatory properties, through producing IL-10 and retinoic acid that
induces the differentiation of Tregs, and by inhibiting the Th17-stimulating capacity of
certain subsets of intestinal DCs (103).
While the immune system of the intestine is important for the containment of intestinal
microbes as described above, experiments using germ-free mice have shown that the
intestinal microbiota plays an important role in the development of the intestinal immune
system (104). In addition, the normal intestinal microbiota has been found to contribute
to intestinal immune homeostasis by refining immune activity (105, 106). For example,
certain microbial species can modulate the immune cell populations present in the
intestine during steady state. Ivanov, Littman and colleagues have shown that
colonization of mice with segmented filamentous bacteria (SFB) can specifically induce
high levels of Th17 cells in the intestine (107). This discovery stemmed from the finding
that mice from different animal facilities showed large variations in the numbers of Th17
cells in gut. This was elegantly traced to the presence of SFB in the intestinal microbiota
of mice from some facilities, but not others. Transfer of SFB to the low Th17, non-SFB
colonized mice increased the presence of intestinal Th17 cells, confirming the causative
role for SFB in inducing intestinal Th17 differentiation. Similarly, the presence of Tregs
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in the gut has been linked to colonization by non-pathogenic Clostridia species (108).
These studies have raised the exciting possibility that intestinal immunity could be
specifically manipulated by altering the composition of the intestinal microbiota.

1.7 INFLAMMATORY BOWEL DISEASE (IBD)
The devastating consequences of inappropriate immune activation in the intestine are
most apparent in the two forms of IBD, Crohn’s disease and ulcerative colitis. Over
200,000 Canadians have IBD, with 9,000 new cases diagnosed each year (109). These
diseases are characterized by chronic, relapsing inflammation of the intestine that causes
persistent diarrhea, rectal bleeding, bloody stool, and fistulae formation (110). The two
forms can be distinguished based on clinical and histological features. Crohn’s disease is
characterized by bowel obstruction, transmural inflammation of the intestine, the
presence of granulomas, and the development of skip lesions, regions of alternating
inflamed and normal tissue. Ulcerative colitis is characterized by bloody stool, severe
diarrhea, and inflammation that does not extend to the muscle wall of the intestine but is
contiguous, without the formation of skip lesions. However, approximately 10% of cases
appear as indeterminate between Crohn’s and ulcerative colitis, although symptoms may
appear later that allow classification of these patients. While the etiology of these
diseases is unknown, a loss of immune tolerance to the intestinal bacteria is observed
patients with IBD (111). The primary trigger remains unknown, but it has been postulated
that infection with certain microbes, primarily Mycobacterium paratuberculosis, serves
as the primary trigger for Crohn’s disease, although this remains controversial (112).
Genetic evidence, discussed below, suggests that alterations in the immune response to
microbes are a key trigger of IBD (113).
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Treatments for these diseases have generally focused on restraining the immune response,
and consist of non-steroidal anti-inflammatory drugs, corticosteroids, and neutralizing
antibodies against inflammatory cytokines (114). Treatment with drugs is done on a trial
basis in each patient, as each may benefit most from a different combination of therapies;
however, ultimately most patients will require surgery, removing inflamed regions of the
intestine, in an effort to control the disease. In ulcerative colitis, surgery can result in the
long-term maintenance of disease remission and can be essentially curative, while in
Crohn’s disease, which differs from ulcerative colitis in that it can affect any region of
the gastrointestinal tract rather than being limited to the colon, the disease often recurs
after surgery. Additionally, as the broadly anti-inflammatory drugs used have negative
consequences such as increased susceptibility to infections, new therapeutic treatments
are needed for theses diseases.

1.7.1

The genetics of inflammatory bowel disease

Genome-wide association studies, which examine single nucleotide polymorphisms from
a large number of diseased and non-diseased individuals to identify disease-associated
polymorphisms, have made a major impact on IBD research (115). These studies have
implicated genetic polymorphisms in several genes related to innate immunity as
associated with increased risk for developing IBD, highlighting the importance of the
recognition of microbes in the maintenance of intestinal homeostasis. Although the
increase in risk of developing the disease that is associated with any of the identified
polymorphisms is low, these genetic associations have been highly informative in our
understanding of the etiology of the disease. Two recent meta-analyses incorporating data
from many different genome-wide association studies of Crohn’s disease and ulcerative
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colitis have increased the number of loci significantly associated with IBD to 99 (116,
117). These loci include genes encoding proteins with roles in innate immunity,
autophagy, and T cell immunity. Although the functional roles of most of these
polymorphisms in the development of disease remain uncharacterized, the investigation
of many of the associated genes has led to a deeper understanding of the mechanisms of
intestinal immunoregulation. The association of Crohn’s disease with nucleotide-binding
oligomerization domain containing (NOD)2, an intracellular pattern recognition receptor
capable of recognizing the muramyl dipeptide portion of bacterial cell wall component
peptidoglycan, has highlighted the role of microbial recognition by innate sensing
mechanisms in protection from IBD. Other associated genes include autophagy related
16-like 1 (ATG16L1), a gene involved in autophagy (118); the IL-23 receptor (119),
important for Th17 functioning; signal transducer and activator of transcription (STAT)3,
a transcription factor that is important for the differentiation of Th17 cells by IL-6 and the
anti-inflammatory effects of IL-10 and G-CSF on myeloid cells (120-122); and Janus
kinase (JAK)2, a receptor associated kinase involved in the signalling pathways induced
by IL-6 and G-CSF (123, 124). Many of the identified genes have been linked to both
Crohn’s and ulcerative colitis, and with other inflammatory diseases. Interestingly, some
of these genes have opposite effects in another inflammatory disease (i.e. the allele is
protective for Crohn’s but permissive for another disease or visa versa). For example,
protein tyrosine phosphatase, non-receptor type (PTPN)22, which is associated with
several autoimmune diseases (125), has opposite effects in Crohn’s disease compared
with Type 1 diabetes and rheumatoid arthritis. These findings have opened up exciting
new avenues of research that will continue to illuminate our understanding of the etiology
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of Crohn’s disease and ulcerative colitis, and the mechanisms of intestinal immune
homeostasis or dysregulation.

1.7.2

Cytokines in inflammatory bowel disease

Cells of inflamed regions of the intestine are known to produce large amounts of several
cytokines, and increased cytokine production can be detected in the bloodstream of
patients with active disease (126-130). Some cytokines have been pursued as therapeutic
targets. The most successful has been the targeting of TNFα by monoclonal antibodies,
which has been approved for therapeutic use in Crohn’s disease (131, 132). Anti-TNFα
also has shown some efficacy in ulcerative colitis, highlighting the role of TNFα in the
pathogenesis of both forms of IBD (133). A neutralizing antibody against the p40 subunit
of IL-12, a key Th1-inducing cytokine, has also been tested (134). However, it is now
known that the p40 subunit is shared with the IL-23 cytokine that is involved in Th17
responses, and therefore it remains unclear if the benefit of anti-p40 is due to the
neutralization of IL-12, IL-23, or both. Administration of recombinant cytokines that may
dampen inflammation, or alternatively enhance deficient immune defenses, has been
tried. IL-10 is a broadly anti-inflammatory cytokine, and IL-10 deficient mice show a
form of spontaneous colitis that has been used as a model of IBD (135). Unfortunately,
administration of IL-10 in humans with IBD has not proven beneficial (136). Two other
cytokines tested include granulocyte-macrophage-colony stimulating factor (GM-CSF)
and G-CSF (5, 137). The rationale behind the use of these cytokines stems from the
observation that some patients with neutropenia develop a colitis resembling IBD, which
is effectively treated with these growth factors (138). This beneficial effect is thought to
involve the stimulation of innate immune defenses in the neutropenic individual.
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However, G-CSF possesses anti-inflammatory properties that may be important in its
effects on IBD (139). The anti-inflammatory functions of G-CSF and its importance in
intestinal immunoregulation are the focus of the present study and will be discussed in
detail throughout this thesis.

1.7.3

The commensal microbiota in IBD

Work in both animal models and in humans has highlighted a key role for the intestinal
microbiota in IBD. It has become clear that the microbiota serves as a source of
stimulation to perpetuate inflammation (105). Inflammation is absent in germ-free mice
in the IL-10-/- model of colitis, suggesting that microbial stimulation drives inflammation
in this model (140). In humans, studies of the composition of the microbiota have
revealed that IBD sufferers harbor an altered intestinal microbiota (141). Determining
whether this altered microbiota is causally linked to IBD or merely a reflection of the
ongoing inflammation is difficult. A strain of mice lacking an adaptive immune system
due to a deficiency in recombination activation gene (RAG)2 and simultaneously
deficient in the transcription factor T-bet develop spontaneous colitis with an altered
intestinal microbiota composition (142). Interestingly, colitis can be induced in wild-type
mice by transferring this altered microbiota, suggesting that the composition of the
microbiota becomes directly colitogeneic in this immune deficient host. This effect was
later traced to the presence of Proteus mirabilis and Klebsiella pneumoniae within the
colitic mice (143). These strains alone transferred colitis to wild-type mice. These results
indicate how an immune defect can shape the intestinal microbiota to induce the
appearance of inflammatory bacterial strains; however, more work is needed to determine
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the relevance of these results to human IBD. Ongoing human microbiome sequencing
efforts may shed light on the role of microbes in the development or perpetuation of IBD.

1.7.4

Probiotics in IBD

Certain strains of bacteria, termed probiotics, have been proposed to have beneficial
effects on human or animal health. Contrary to the inflammatory response that is
observed to most pathogens studied, some strains of bacteria have been shown to have
anti-inflammatory effects, which could have therapeutic implications for IBD (144).
Clinical trials of various strains have had little success, especially for Crohn’s disease,
while more promising results have been obtained in ulcerative colitis. However, these
clinical trials have generally been small, with considerable variation in the strain of
probiotic organism utilized, the dose administered, and other study parameters, making
firm conclusions about the effectiveness of probiotics difficult. It has been observed that
the intestinal microbiota of IBD patients shows less species diversity than non-diseased
individuals (145). One approach to developing probiotic strains for IBD would be to
identify what, if any, strains are lacking in IBD patients vs. non-diseased individuals.
This approach has led to the proposal that Faecalibacterium prausnitzii may be a
candidate therapeutic for Crohn’s disease (146). However, the efficacy of this strain in
IBD awaits further study. In addition, as each individual harbors a unique microbiota, a
“one size fits all” approach using a single microbe may not be the most effective.
Therefore, future probiotic therapies may be best tailored to the particular alteration
present in each individual.
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1.7.5

Mouse models for the study of inflammatory bowel disease

Mouse models have been used extensively in the study of intestinal inflammation (147,
148). Although no perfect model of human IBD exists, multiple different models have
been developed, each with strengths and weaknesses in regard to modeling human IBD.
Chemically induced models are generally the easiest to perform, and are highly
reproducible (148). Perhaps the most widely used model is the dextran sulfate sodium
(DSS) model (148). This model benefits from a high degree of reproducibility and is
technically simple to perform. However, at least in the acute stage, this model does not
depend on T cell responses (149), which do appear to play a role in human chronic IBD
(113). Nonetheless, this model has been very useful for the study of mechanism of acute
intestinal inflammation. DSS is thought to act by killing intestinal epithelial cells,
breaking down the mucosal barrier and leading to massive inflammation (147). In
addition to acute inflammation, this model can be used to study chronic inflammation by
using multiple rounds of low-dose DSS administration (150). After several rounds of
DSS administration, the mice begin to exhibit a chronic form of relapsing and remitting
colitis that may more closely mimic human IBD. However, this model may be more
challenging to optimize than the acute inflammation model. Another chemically induced
acute colitis model is the trinitrobenzene sulfonate (TNBS) model, which acts by
haptenizing luminal antigens and causing intestinal inflammation dependent upon the
intestinal microbiota and the adaptive immune system (148). While this model allows the
assessment of adaptive immune mechanisms in intestinal inflammation, its effects are
highly strain dependent, with some mouse strains (namely C57BL/6) showing resistance
to TNBS-induced colitis unless a pre-sensitization step is used (147). Other commonly

25

used mouse models of IBD include IL-10-/- mice, which succumb to spontaneous
intestinal inflammation (135), and the CD4+CD45RBhigh T-cell transfer model (61).
Both of these models involve adaptive immunity and are driven by the intestinal
microbiota, but are technically more challenging to perform than the chemically-induced
colitis models or show a great degree of variability in the course of intestinal
inflammation between individual mice (148).

1.8 GRANULOCYTE-COLONY STIMULATING FACTOR
The three colony-stimulating factors, granulocyte/macrophage colony-stimulating factor
(GM-CSF), macrophage colony-stimulating factor (M-CSF) and G-CSF, were first
identified by their ability to generate mature myeloid cells from bone-marrow derived
precursor cells in vitro (151). Since then, their biological roles have been broadened
significantly, including immune responses, cell proliferation and survival, and
malignancy (152, 153). G-CSF was demonstrated to promote the generation of the
granulocytic lineage, mainly neutrophils (154, 155), and mobilize hematopoietic stem
cells from bone marrow into the peripheral circulation (156). These activities have been
exploited medically to alleviate chemotherapy-induced neutropenia and to engraft
peripheral blood stem cells without short-term or long-term consequences (153). Recent
work in animal models, as well as extensive clinical experience, has shown that G-CSF
has several important activities in addition to its effects on neutrophils and hematopoietic
cells (3), which includes neuroprotection, cardiac cell generation and repair, and
immunomodulation (157-159). Unlike GM-CSF and M-CSF, G-CSF has been shown to
have immunoregulatory effects when exogenously administered to human patients or
animals (158), suggesting a role in maintaining local immune homeostasis in tissues
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where it is highly produced. Although much has been learned through administration of
exogenous recombinant G-CSF into human and animal subjects, understanding of the
role of endogenous G-CSF in cells other than the granulocytic lineage has lagged behind.

1.8.1

Production of G-CSF

Regulation of G-CSF transcription is mainly mediated by a 300 base pair region upstream
of the transcription initiation site, containing binding sites for transcription factors such
as nuclear factor-κB and nuclear factor-IL6, and hence expression of G-CSF is thought to
be downstream of several pathways common to inflammation or injury responses (160).
Inflammatory mediators such as IL-1, TNF, TLR ligands including microbial components
such as lipopolysaccharide (LPS) and endogenous molecules such as the acute-phase
protein serum amyloid A (SAA) (161) have been shown to induce G-CSF production. In
addition to the induction of G-CSF production by TLR stimulation or inflammatory
cytokines mainly produced by innate immune cells, regulation of G-CSF by the T-cell
cytokine IL-17 has emerged as a key mechanism eliciting neutrophil production (162,
163). Th17 cells are key mediators of intestinal inflammation, and are found in high
numbers in the gut (67). Through release of IL-17, Th17 cells can induce G-CSF as well
as chemokine expression that increases production and recruitment of neutrophils to sites
of inflammation. IL-17 can also enhance G-CSF production by human colonic subepithelial myofibroblasts, suggesting that this mechanism of G-CSF production is of
relevance to intestinal homeostasis (164). G-CSF can also be produced by bone marrow
stromal cells, fibroblasts, macrophages, and endothelial cells (165).
Normal serum levels of G-CSF remain low, typically at the limits of detection by
conventional ELISA (166). However, serum levels are increased upon acute infection
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(167-169) and have been observed to be increased in the chronic inflammatory disease
rheumatoid arthritis (170). Increased local production of G-CSF within tissues is
observed in the synovium in rheumatoid arthritis (170), in lamina propria mononuclear
cells isolated from patients with actively inflamed IBD (129), and in the
ischemia/reperfused lung (171) and gut (172). We have detected high levels of G-CSF in
isolated normal human colon lamina propria cells and mouse colon tissue (173).
However, the source of endogenous intestinal G-CSF under normal conditions and its
role in intestinal immune homeostasis remain to be explored.

1.8.2

G-CSF as an immune modulator

Injection of G-CSF induces neutrophilia in healthy subjects, and G-CSF is effectively
used therapeutically to correct neutropenia, such as in patients undergoing chemotherapy
(174). Studies using mice deficient in G-CSF or G-CSF receptor (G-CSFR) have
demonstrated a key role for G-CSF in maintaining circulating neutrophil numbers in
steady state (154, 175) and in mobilizing neutrophils during infection with Listeria
monocytogenes (175) or Pseudomonas aeruginosa (176). However, these mice still
harbor ~25% of basal circulating neutrophils and have no apparent defect in mobilizing
neutrophils in infection with Candida albicans (177), indicating the presence of G-CSFindependent granulopoiesis. G-CSF also acts on neutrophils to enhance their maturation,
survival, and effector functions, such as phagocytosis, bactericidal activity, antibodydependent cellular toxicity, and cytokine production (178). Thus, G-CSF, together with
GM-CSF and M-CSF, is often considered an immunostimulatory or proinflammatory
factor (152).
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In addition to its immunostimulatory effects on neutrophils, G-CSF has direct and
indirect immunomodulatory effects on other immune cells. In vivo administration of GCSF in both animal models and humans has concordantly shown immunomodulatory
effects, as exemplified by: suppressing the production of proinflammatory cytokines by
peripheral blood mononuclear cells, inducing anti-inflammatory DCs, and enhancing IL4 but reducing interferon γ production in lymphocytes (179-183). In vitro, G-CSF inhibits
LPS-induced inflammatory cytokine production including TNFα and IL-12 in
monocytes/macrophages (6, 120, 184), and TLR-induced IL-8 and TNFα production in
neutrophils (185). Injection of G-CSF into human patients and volunteers has
demonstrated mobilization of DCs that induce IL-4 and IL-10 expression from T cells,
through a mechanism that may involve the release of IL-10 into the serum of G-CSFinjected individuals (186, 187). Therefore, G-CSF may exhibit immunomodulatory
effects on cells of the monocyte lineage both systemically by mobilizing distinct cell
subsets and inducing IL-10 production and locally by inhibiting inflammatory cytokine
production within monocytes/macrophages, although the direct effects of G-CSF on DC
function remain unclear.
Interestingly, a sharp contrast with the immunomodulatory effects of G-CSF has been
demonstrated in GM-CSF (188). For example, systemic administration of GM-CSF
induced enhanced circulating proinflammatory cytokine levels in response to subsequent
LPS challenge (189) and, in humans, caused inflammatory reactions and fever (190). Ex
vivo derived monocytes from GM-CSF-treated cancer patients showed enhanced
production of proinflammatory cytokines in response to LPS (191). Although much less
is known regarding the role of M-CSF in immune modulation, M-CSF was suggested to
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have a similar immune stimulatory effect as GM-CSF (152, 192). However, M-CSF was
also shown to inhibit the stimulatory effects of GM-CSF, leading to immune suppression
and tolerance, possibly through reciprocal modulation of macrophage phenotype (152).
GM-CSF has also shown to preferentially induce macrophage differentiation into
classically-activated, pro-inflammatory macrophages (M1); whereas, M-CSF induces
differentiation into alternatively activated (M2) macrophages, which are considered antiinflammatory and contribute to tissue repair (193, 194). Treatment of bone-marrow
derived macrophages with G-CSF did not up-regulate mRNA expression of known M1or M2-specific markers such as inducible nitric oxide synthase, arginase, or chitinase 3like-3, also known as Ym1 (A. Martins and S.O. Kim, unpublished observations). These
results suggest that the immunomodulatory effect of G-CSF is distinct from the two other
CSFs.

1.8.3

G-CSF signalling pathways involved in immunomodulation.

G-CSF signals through the G-CSF receptor via homodimerization of the receptor and
activation of the JAK/STAT pathway (195). Activation results in internalization,
ubiquitination, and degradation of the receptor thereby downregulating further
responsiveness to G-CSF. A mutant receptor that lacks the ubiqutination site at amino
acid 762 (K762R/G) shows hyper-responsiveness to G-CSF, highlighting the role of
ubiquitination in regulation of G-CSF responses (196). Suppressor of cytokine signalling
3 (SOCS3) expression is induced by G-CSFR activation, which is a key negative
regulator of G-CSF responses via preventing JAK activation by binding to the receptor
(197). Akt is rapidly activated upon G-CSFR activation through Src, independent of the
JAK/STAT pathway (198). As with the well-studied anti-inflammatory cytokine IL-10,
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one key target of G-CSF signalling is STAT3. We and others have shown that the
activation of STAT3 in macrophages is important for the down-regulation of LPSinduced TNF by G-CSF (6, 120). STAT3, activated by G-CSF, blocks LPS- or E. coliinduced c-Jun N-terminal kinase (JNK) activation, which is a crucial step for the
suppression of TNF production in macrophages (6). While IL-10 induces STAT3
phosphorylation at Y705 and S727, S727 phosphorylation is not required for its
inhibitory effects (199). STAT3 is phosphorylated at the Y705, but not S727, by JAK2 in
response to G-CSF. G-CSF-induced Y705 phosphorylation of STAT3 is important for the
inhibition of JNK activation and pro-inflammatory cytokine production by macrophages
(6). In addition, inhibition of JNK requires de novo protein synthesis, suggesting that
STAT3 mediated transcriptional activity is required for this effect of G-CSF (6). Further
signalling details of the STAT3-mediated inhibition of TNFα production by G-CSF await
further study. The STAT3-induced ETS-family transcriptional repressor ETV3 and
transcriptional corepressor strawberry notch homologue 2 (SBNO2) have been implicated
in the anti-inflammatory effects of IL-10 (199), but have not yet been examined in the
context of the anti-inflammatory effects of G-CSF. Intriguingly, while IL-6 also potently
activates STAT3, it does not share the inhibitory effects of IL-10 and G-CSF. Recently it
has been shown that in the absence of SOCS3, IL-6 can generate an anti-inflammatory
response similar to IL-10 (199). Therefore, it will be interesting to examine the role of
SOCS3 in the anti-inflammatory effect of G-CSF.
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1.8.4

Contrasting effects of G-CSF on arthritis and inflammatory
bowel diseases

Considering the pleiotropic effects of G-CSF, it is not surprising that both beneficial and
detrimental roles of G-CSF have been noted in several animal disease models and human
conditions, exemplified by arthritis and inflammatory bowel diseases. In a Mycobaterium
tuberculosis-induced joint inflammation model, G-CSF has a protective role in disease
severity, at least in part due to reduced antigen presenting capacity and subsequent
reduction in lymphocyte proliferation and IFN-γ secretion (200). In contrast, G-CSFdeficient mice are protected from arthritis (201) and neutralizing G-CSF antibody is as
effective as TNFα neutralization in a collagen-induced arthritis model (202). The
detrimental effect of G-CSF in collagen-induced arthritis has been attributed to the
production and mobilization of neutrophils (203). In a human trial, G-CSF administration
was shown to exacerbate inflammation in at least a minority of rheumatoid arthritis
patients (204). Blockade of G-CSF may therefore be beneficial in patients with arthritis,
and targeting G-CSF through blocking antibodies has been suggested as a therapeutic
modality (205).
As described above, Crohn’s disease and ulcerative colitis are chronic, relapsing
inflammatory diseases of the digestive tract, which appear to result from inappropriate
immune reaction to the commensal microbiota. The precise etiology of these diseases
remains uncertain, but evidence based on animal disease models and human genome
wide studies points to defective immunoregulation as well as deficient inflammatory
responses. Initial reports suggested that G-CSF plays a detrimental role in IBD through
enhancing neutrophil survival in inflammatory lesions (206). However, clues to a
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beneficial role of G-CSF in IBD treatment come from the observation that glycogen
storage disease 1b, a disease in which there are defects in neutrophil production and
function, is often associated with intestinal inflammation that is similar to Crohn’s
disease, and that the intestinal manifestation is effectively treated with systemic G-CSF
administration (138). Small, open-labeled trials using G-CSF for active Crohn’s disease
have given some indication of efficacy; however, its efficacy remains to be proven in
larger trials (5, 179). The beneficial effects of systemic G-CSF administration in human
IBD also seem to correlate with its ability to induce IL-10-producing T cells and
plasmacytoid dendritic cells, highlighting an anti-inflammatory role for G-CSF (179).
However, reports from the group of A.W. Segal have supported the hypothesis that
defective immune responses play a role in IBD, and it was shown that G-CSF can correct
the defect in neutrophil chemotaxis that is observed in Crohn's disease (207). Recently,
IBD has been suggested to result from an dysfunction of macrophages, in which reduced
production of several cytokines, including G-CSF, in response to inflammatory stimulus
results in reduced neutrophil recruitment, defective bacterial clearance, and the
development of chronic inflammation (208, 209). The pro-survival effects of G-CSF on
diverse cell types may also come into play in IBD. In rodents, G-CSF attenuates DSSinduced colitis by a mechanism that may involve the inhibition of epithelial cell apoptosis
(210). Therefore, G-CSF may be beneficial in IBD due to the strengthening of the
mucosal barrier, as well as its anti-inflammatory effects.
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MACROPHAGES‡
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reproduced with permission of John Wiley & Sons, Inc.

50

2.1 Introduction
Lactobacillus is a common constituent of the indigenous microbiota in the human
intestinal and urogenital tracts (1) and strains of this genus have been used as probiotics,
defined as ‘live microorganisms which when administered in adequate amounts confer a
health benefit on the host’ (2). Although lactobacilli, and probiotics in general, have been
extensively studied for their role in ameliorating various inflammatory ailments (3-8), the
mechanism(s) involved in their anti-inflammatory effects is not yet well understood.
Studies over the last several years have revealed potential anti-inflammatory mechanisms
of commensal microbes at the level of mucosal epithelial cells, where the microbes
directly modulate production of inflammatory cytokines through inhibiting the key
signalling molecule, nuclear factor κB (NF-κB) (9, 10), and proteasomes (11). Recent
studies have also indicated that the anti-inflammatory effects of probiotics are not limited
to the level of intestinal mucosa but modulate the host immune responses at distant sites
(12). The extra-intestinal anti-inflammatory effects produced by oral or systemic
(subcutaneous) administrations of probiotics have been demonstrated in various
inflammatory, autoimmune and atopic diseases including arthritis, dermatitis and
allergies (12-16).
Most microbes harbour pathogen-associated molecular patterns and induce inflammatory
cytokines through activating pattern recognition receptors. Probiotics are inefficient in
inducing pro-inflammatory cytokines but can effectively modulate host immune
responses, possibly through immunomodulating autocrines and/or paracrines (3, 16, 17).
Several microbes and parasites modulate immune responses and inflammation process to
gain access to the host and proliferate. For example, the parasitic helminths potently
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stimulate IL-10 production and induce an anti-inflammatory environment in the host (18).
Protozoan parasite Toxoplasma gondii inhibits nitric oxide (NO) production and induces
anti-inflammatory responses through transforming growth factor-β1 (TGF-β1) (19).
Mycobacterium inhibits interferon-γ (IFN-γ) production and responses in macrophages
through IL-6 secreted from Mycobacterium-infected macrophages (20). Although various
strains of probiotics induce anti-inflammatory effects in vitro and in experimental animal
models, the mediators and mechanisms responsible for their effects have not yet been
explored (5, 7, 16, 17, 22).
Macrophages are the major source of various cytokines and well populated in the normal
intestinal lamina propria close to the epithelial layer and Peyer’s patches, directly
interacting with penetrating commensal bacteria (23). Direct interaction between
commensal bacteria and the large number of infiltrating peripheral monocytes at the onset
of or during active intestinal inflammation has been shown to be involved in the
pathogenesis of inflammatory diseases (24-27). Therefore, immune responses and
cytokines released by macrophages in response to probiotics are particularly crucial for
understanding the mechanism(s) of their immunomodulating effects on the host. In this
study, we examined an immunomodulating mechanism of two well-studied strains of
Lactobacillus rhamnosus, L. rhamnosus GG and GR-1, in macrophages. L. rhamnosus
GG (GG), which was isolated from the stool of a healthy individual, is one of the most
studied probiotic strains and its role in ameliorating inflammatory ailments has been
demonstrated in various animal disease models and human patients (3, 8, 28-30). L.
rhamnosus GR-1 (GR-1) is a urogenital isolate that possesses a number of properties
considered important for urogenital probiotics (31, 32). This study showed that both GG
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and GR-1 potently induced production of granulocyte-colony stimulating factor (G-CSF),
which was a crucial mediator for suppressing tumour necrosis factor-α (TNF) production
through activating signal transducer and activator of transcription (STAT)-3 and
subsequently inhibiting activation of c-Jun-N-terminal kinases (JNKs) in macrophages.
These results define G-CSF as a key mediator through which probiotics, particularly L.
rhamnosus, elicit immunomodulating effects on the host.
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2.2 MATERIALS AND METHODS
2.2.1

Cell cultures, bacteria and reagents

Mouse bone marrow-derived immortalized macrophages (BMDIM, obtained from Dr B.
Aggarwal; Houston, TX) and human THP-1 monocytes (ATCC, Manassas, VA) were
grown in 75 cm2 flasks containing complete RPMI 1640 medium supplemented with 10%
fetal bovine serum (FBS) (Hyclone), 100 U ml−1 of penicillin, 100 µg ml−1 of
streptomycin (Invitrogen, Carlsbad, CA), 1 mM sodium pyruvate and 1 mM MEM nonessential amino acids at 5% CO2, 37°C. Lactobacillus spp. were grown anaerobically in
de Man, Rogosa, Sharpe (MRS) broth (Becton Dickinson, Sparks, MD) for 48 h at 37°C.
L. rhamnosus GR-1 was isolated as previously described (33) and L. rhamnosus GG was
obtained from ATCC (Mannasas, VA). E. coli GR-12 and E. faecalis 1311 were from our
strain collection and grown overnight aerobically in Luria-Bertani broth. All bacteria
were harvested by centrifugation (3000 g, 15 min) at the stationary growth phase and
washed three times with phosphate buffered saline (PBS) and subsequently diluted to
obtain final cell densities in RPMI 1640 medium without antibiotics. LPS from E. coli
O111:B4 was purchased from List Biological Laboratories (Campbell, CA). Antibodies
for phospho-specific (Tyr705 and Ser727) STAT3, (Tyr701) STAT1, (Tyr694) STAT5,
phospho-specific (Thr180/Tyr182) p38, phospho-specific (Thr202/Tyr204) ERK1/2,
phospho-specific (Thr183/Tyr185) SAPK/JNK and antibodies for their counterpart wildtype proteins were purchased from New England Biolabs (Beverley, MA). IL-10 and GCSF neutralizing antibody was obtained from eBioscience (San Diego, CA) and R&D
Systems (Minneapolis, MN) respectively.
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2.2.2

Primary peritoneal macrophages from wild-type C57BL/6, GCSFR–/– and IL-10–/– mice

Homozygote IL-10-deficient (C57BL/6-IL10tm1Cgn; IL-10–/–) and control strain
(C57BL/6j) mice were purchased from The Jackson Laboratory (Bar Harbor, MA).
Homozygote G-CSFR-deficient (G-CSFR–/–) mice were provided by D.J. Link
(Washington University Medical School, St Louis, MO). Primary peritoneal macrophages
from these mice were obtained by normal saline lavage as described previously (34).
Briefly, mice received intraperitoneal injection of 3% thioglycollate (1 ml) and peritoneal
macrophages were harvested 4 days post injection by lavage of the peritoneal cavity with
normal saline. The cells were washed and incubated overnight before use.

2.2.3

Generation of bacterial spent culture supernatant and
macrophage cell culture CM, and treatments

Cultures of lactobacilli, E. coli GR-12 and E. faecalis 1311, were grown to an optical
density of 1.0 at 600 nm (representing approximately 109 cfu ml−1). Bacteria-free spent
culture supernatant was collected by centrifugation at 6000 g for 10 min at 4°C. SCS was
separated from cell pellet and passed through a 0.22 µm pore size filter unit (Nalgene,
Rochester, NY). BMDIM, primary peritoneal macrophages, or human monocytic THP-1
cells were grown in RPMI culture medium and approximately 2x106 cells per well were
plated into six-well cell culture plates (2 mL media per well). Macrophages were then
treated with bacterial SCS (1/20 dilution) or live bacteria (10 µL/mL of a bacterial
suspension with an OD at 600 nm of 1, approximately 10 cfu per macrophage) in
antibiotic-free culture medium. After 6 h of exposure, cells were washed with PBS and
replaced with fresh cell culture medium with antibiotics. The overnight macrophage
culture medium was used as CM. For assaying, the CM was further diluted with fresh
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culture medium (1:1) to supplement nutrients and used on freshly plated macrophages.
For controls, overnight CM of macrophages without treatments was used.

2.2.4

Cell lysates and immunoblotting

Total cell lysate extraction and Western blot analysis were performed as previously
described (35). Briefly, cells were lysed in ice-cold cell lysis buffer containing 20 mM
MOPS, 15 mM EGTA, 2 mM EDTA, 1 mM Na3VO4, 1 mM dithiothreitol, 75 mM βglycerophosphate, 0.1 mM phenylmethylsulphonyl fluoride, 1 µg ml−1 aprotinin, 10 µg
ml−1 pepstatin A, 1 µg ml−1 leupeptin and 1% Triton X-100 and then sonicated on ice.
Cell extracts were obtained by centrifuging the homogenate at 18,000 g for 10 min. These
extracts were electrophoretically resolved in ready-made 10% SDS-polyacrylamide gels
(Bio Rad), followed by transfer onto nitrocellulose membranes. Membranes were
subsequently blocked with 5% skim milk for 30 min, immunoblotted with antibodies and
developed using an enhanced chemiluminescence detection system (ECL; Pierce
Bioscience).

2.2.5

Adenoviral (Ad) and retroviral viral infections

A recombinant, replication-deficient, adenovirus vector encoding the human STAT3
Tyr705(r)Phe (AdSTAT3-DN) and an identical construct lacking the insert (Ad0) were
provided by L. Williams (Imperial College, London, UK). MKK7 wild-type adenovirus
was obtained from J. Han (The Scripps Research Institute, La Jolla, CA). The
recombinant viruses were purified and concentrated as described previously (36). Human
monocytic THP-1 cells were transiently infected with adenovirus at the multiplicity of
infection (moi) of 50 for 1 h in serum-free medium. Cells were then washed and
recultured in growth medium for 24 h. Puromycin resistance gene-containing retroviral
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vector constructs for dominant active human STAT3α-C were obtained from J.F.
Bromberg (Memorial Sloan-Kettering Cancer Center, New York). Viruses were
generated in Phoenix Amphotropic producer cells using the calcium phosphate method of
transfection (37). Viruses were produced at 32°C, and virus-containing medium was
collected 36 h post transfection and filtered through a 0.45 µm filter. THP-1 cells were
plated in six-well plates at a density of 5x105 cells per well. One round of retroviral
infection was performed by replacing medium with 2 ml of retrovirus and retrovirusinfected cells were selected by culturing in media containing puromycin (10 µg ml−1).
The retrovirus-infected cells were maintained in culture medium containing puromycin (5
µg ml−1) and then normal culture media 24 h before experiments.

2.2.6

Cytokine analysis

Production of IL-10 and G-CSF in macrophage cell culture supernatants was measured
using quantitative enzyme-linked immunosorbent assay kits purchased from eBioscience
and R&D Systems respectively. Standard curves for each cytokine were generated using
purified recombinant proteins of known concentration provided by the manufacturer.
TNF bioassays were used to measure TNF production as previously described (38).

2.2.7

Quantitative real-time PCR

Expression of gene transcripts in macrophages was quantified on the Rotor-Gene
RG3000 quantitative multiplex PCR instrument using the Brilliant SYBR Green PCR
Master Mix (Applied Biosystems). Total cellular RNA was isolated using TRIzol (Life
Technologies) according to the manufacturer’s instructions. Briefly, 1 µg of total RNA
was reverse transcribed by using oligo(dT) primers and the Superscript II reverse
transcriptase system (Invitrogen) according to the manufacturer’s recommendations.
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Oligonucleotide

primers
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CTGGAAATAGCTCCCAGAAA-3′
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following:
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TNF,

5′-

5′-CATTTGG

GAACTTCTCATCC-3′ (3′ primer); for IL-10, 5′-TGCTATGCTGC CTGCTCTTA-3′ (5′
primer) and 5′-TCATTTCCGATAAGGCT TGG-3′ (3′ primer); for G-CSF, 5′CCGATAGAGCCTGCAG

GAGA-3′
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(5′

(3′

primer)

primer);
(5′

TTGCTGTTGAAGTCGCAGGAG-3′ (3′ primer).
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and

5′5′5′-
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2.3 Results
2.3.1

Lactobacillus rhamnosus GR-1 and GG suppress
Escherichia coli-induced inflammatory cytokines through a
paracrine route in macrophages

We first examined how macrophages react to Lactobacilli by assessing production of
TNF in response to two strains of live L. rhamnosus GG and GR-1 in C57BL/6 mouse
bone marrow-derived immortalized macrophages (BMDIM). As shown in Fig. 2.1A, live
L. rhamnosus GG and L. rhamnosus GR-1 are much less potent than the pathogenic
bacteria E. coli GR-12 and Enterococcus faecalis 1311 in inducing production of TNF.
Treatments with bacterial spent culture supernatant induced the similar profile of TNF
production (data not shown). As macrophages are a main source of cytokines including
anti-inflammatory cytokines, we hypothesized that GG- or GR-1-treated macrophages
can indirectly modulate self or other macrophages through autocrine/paracrine routes. To
examine their indirect immunomodulating effects, we obtained conditioned media (CM)
from BMDIM treated with either E. coli, E. faecalis, L. rhamnosus GG, or GR-1 and
assessed their effects on TNF production induced by E. coli-SCS. As shown in Fig. 2.1B,
pretreatment with CMs obtained from live GG- or GR-1-treated BMDIM (GR-1-CM or
GG-CM respectively) strongly suppressed TNF production induced by E. coli-SCS.
However, this effect was not detected when the pretreatment was less than 30 min (data
not shown) and not by CMs prepared from E. coli- or E. faecalis-treated cells (Fig. 2.1B).
CMs prepared from SCS of GG or GR-1 but not from heat-killed GG or GR-1 also
suppressed TNF production (data not shown). Although E. coli or E. faecalis induced
large quantities of TNF in BMDIM (Fig. 2.1A), CM prepared from E. faecalis- or E. colitreated cells contained very little TNF (data not shown) because the cells used for CM
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generation were washed with PBS after 6 h of bacterial treatment before overnight
culture for the generation of CM. In addition, the CM was further diluted with fresh
culture media (1:1 ratio) before treating fresh cells. Therefore, TNF present in the CM
had little additive effects on subsequent TNF measurements (Fig. 2.1B). Production of
TNF peaked at 5–6 h after E. coli-SCS treatment (data not shown). Real-time polymerase
chain reaction (PCR) analysis further showed that GG-CM or GR-1-CM down-regulated
TNF mRNA expression induced by live E. coli in BMDIM (Fig. 1C). We also examined
whether the inhibitory effect can be detected in human monocytic cell line, THP-1 cells.
As shown in Fig. 2.1D, CMs prepared from live GG- or GR-1-treated THP-1 cells also
suppressed TNF production induced by E. coli-SCS in THP-1 cells.
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Figure 2.1: Anti-inflammatory paracrine effects of L. rhamnosus GR-1 (GR-1) and
GG (GG). A. Production of TNF by non-treated (CNT) or live bacteria-treated bone
marrow-derived immortalized macrophages (BMDIM) for 9 h was analysed in the cell
culture media. B–D. Inhibition of TNF production (B and D) and mRNA expression (C)
by L. rhamnosus-treated macrophage-conditioned medium. BMDIM (B and C) or human
monocytic cell line THP-1 cells (D) were treated with none (CNT) or E. coli-spent
culture supernatant (SCS) in the presence or absence of pretreatment for 45 min with
conditioned media (CM) obtained from non-treated (none), live E. coli-, E. faecalis-, L.
rhamnosus GG- or GR-1-treated BMDIM or THP-1 cells. Expression of TNF mRNA (C)
was measured 4 h after treatment by real-time PCR analysis. Production of TNF was
measured 9 h after treatments using a bioassay as described previously (38). Data are
expressed as means + SD of three independent experiments.
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2.3.2

Lactobacillus rhamnosus GG and GR-1 potently induce
production of anti-inflammatory cytokines

To identify mediators that are involved in the TNF-suppressive effect of GG and GR-1,
we examined the presence of inhibitory cytokines including IL-10 and G-CSF in CMs
prepared from live E. coli-, GG- or GR-1-exposed BMDIM. IL-10 was detected up to
200–300 pg ml−1 in all E. coli-, GG- or GR-1-exposed cells. Surprisingly, G-CSF was
detected at levels up to 50–70 ng ml−1 in GG- or GR-1- exposed BMDIM (Fig. 2.2A). E.
coli induced ∼25 ng ml−1 G-CSF, about half of the concentration induced by GG. Similar
results were obtained from human THP-1 cells (data not shown). Consistent with protein
production, live GG or GR-1 up-regulated mRNA expression of IL-10 and G- CSF up to
6–8 and 17–20-fold, respectively, in BMDIM (Fig. 2.2B).
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Figure 2.2: Production of anti-inflammatory cytokines in live bacteria-treated
BMDIM. BMDIM were exposed to none (CNT), live E. coli, L. rhamnosus GG (GG) or
L. rhamnosus GR-1 (GR-1) to obtain conditioned medium (CM). A. Presence of IL-10
and G-CSF in the CM was analysed 18 h after treatment using ELISA assays. B.
Expression of mRNAs for IL-10 and G-CSF were measured by using real-time PCR
analysis 12 h after treatment. Data are expressed as means + SD of three independent
experiments.
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2.3.3

G-CSF is the key inhibitory factor responsible for L.
rhamnosus-induced suppression of TNF production

Both IL-10 and G-CSF have been shown to have TNF-suppressing effects on
macrophages (39-41). As GR-1 induced IL-10 and G-CSF production (Fig. 2.2), we
examined whether GR-1-induced suppression of TNF production was mediated through
IL-10 and/or G-CSF. As shown in Fig. 2.3A, lipopolysaccharide (LPS) induced TNF
production in THP-1 cells, which was suppressed by CM prepared from GR-1-exposed
THP-1 cells. Depletion of IL-10 by neutralizing antibodies from the GR-1-CM only
marginally reversed the suppression of TNF production, whereas depletion of G-CSF
reversed ∼95% of the suppression. As the neutralizing IL-10 antibody might not
completely block IL-10 and small amounts of IL-10 could be enough to suppress TNF
production, we further examined the role of IL-10 and G-CSF using primary peritoneal
macrophages deficient in IL-10 or G-CSF-receptor (G-CSFR-/-) respectively. Primary
peritoneal macrophages isolated from wild-type (C57BL/6) or IL-10 deficient
(C57BL/6IL−10–/–) mice were treated with live GR-1 to obtain conditioned media, GR-1CMwt and GR-1-CMIL−10–/– respectively. Fresh primary peritoneal macrophages isolated
from wild-type mice were treated with LPS (100 ng ml−1) in the presence or absence of
the CM pretreatment. As observed in BMDIM or THP-1 cells, both GR-1-CMwt and GR1-CMIL−10–/– suppressed TNF production to similar extents (Fig. 2.3B), indicating that IL10 is not required for suppression. Involvement of G-CSF was further examined using GCSFR–/– macrophages. Macrophages isolated from wild-type or G- CSFR–/– mice were
treated with LPS (100 ng ml−1) in the presence or absence of GR-1-CMwt pretreatment
and the production of TNF was measured. As shown in Fig. 2.3C, TNF production in
wild-type macrophages was potently suppressed by GR-1-CM. However, TNF
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production in LPS-activated G-CSFR–/– macrophages was not suppressed by GR-1CMwt. We then examined whether the concentration of G-CSF present in GR-1-CM was
high enough to have TNF-suppressive effects in THP-1 cells using human recombinant
G-CSF (hG-CSF). As shown in Fig. 2.3D, hG-CSF suppressed TNF production in a dosedependent manner at a concentration range from 100 to 500 pg ml−1. These data
supported a crucial role of G-CSF but not IL-10 in mediating TNF suppression induced
by GR-1-CM in macrophages.
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Figure 2.3: G-CSF is required for the L. rhamnosus GR-1-CM-induced inhibition of
TNF production in LPS-activated macrophages. A. THP-1 cells were exposed to LPS
(100 ng ml−1) without (CNT) or with pretreatment (45 min) of GR-1-CM for the time
indicated. G-CSF- or IL-10-depleted GR-1-CMs from THP-1 cells were obtained by
incubating with anti-human G-CSF (0.1 µg ml−1) or IL-10 (0.3 µg ml−1) neutralizing
antibodies in GR-1-CM for 1 h. B. Isolated primary mouse peritoneal macrophages were
exposed to LPS with or without pretreatment with GR-1-CM prepared from wild-type or
IL-10–/– peritoneal macrophages (GR-1-CMwt and GR-1-CMIL10–/– respectively). C.
Mouse peritoneal macrophages were isolated from wild-type or G-CSFR–/– mice and
exposed to LPS (100 ng ml−1) with or without pretreatment with GR-1-CM prepared
from wild-type primary macrophages. D. THP-1 cells were treated with LPS (100 ng
ml−1) with or without various concentrations of recombinant human G-CSF. Production
of TNF was measured 9 h after LPS-treatment as described previously (38). Data are
expressed as means + SD of three independent experiments.
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2.3.4

GR-1-CM preferentially induces tyrosine phosphorylation of
p38 MAPK and STAT3

To investigate the mechanism of GR-1-CM-mediated TNF suppression, we first
examined several signalling molecules known to be involved in anti-inflammatory
pathways in macrophages. Among them, STAT-3 was strongly activated by GR-1-CM
(Fig. 2.4A). GR-1-CM preferentially induced phosphorylation of STAT3 at tyrosine-705
(Y705), which is required for STAT3 activation, but not at serine-727 (S727). In contrast,
E. coli-CM strongly induced phosphorylation of STAT3 at both tyrosine and serine
residues. E. coli-CM also induced phosphorylation of STAT1 and STAT5 at Y-701 and
Y-694 respectively. GR-1-CM slightly induced STAT5 Y-694 phosphorylation but
STAT1 phosphorylation was not detected. Phosphorylation at S727 of STAT3 has been
shown to be mediated through the mitogen-activated protein kinases (MAPK) ERK1 and
ERK2 (42-46). Therefore, we examined whether GR-1-CM or E. coli-CM induced ERK
activation. Indeed, E. coli-CM induced phosphorylation of ERK1 and ERK2 at their
activation sites after 15 min of treatment, whereas GR-1-CM did not stimulate ERK1 and
2 phosphorylation (Fig. 2.4B). E. coli-CM also induced phosphorylation of other MAPKs
including JNKs and p38, but GR-1-CM induced only p38 MAPK phosphorylation (Fig.
2.4B).
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Figure 2.4: STAT3 Y-705 phosphorylation is preferentially induced by GR-1-CM
relative to E. coli-CM. BMDIM were treated with GR-1-CM or E. coli-CM for the time
indicated. Total cell lysates (35 µg per lane) were analysed by Western blotting using
phospho-specific or anti-peptide antibodies against the various protein kinases indicated.
Results are representative of two independent experiments.
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2.3.5

G-CSF is the factor responsible for JAK2-STAT3 pathway
activation in GR-1-CM-treated macrophages

To examine whether the STAT3 Y705 phosphorylation was induced by G-CSF or IL-10,
we used human IL-10 or G-CSF neutralizing antibodies. As shown in Fig. 2.5A,
phosphorylation of STAT3 at Y705 was not detected in G-CSF-depleted GR-1-CM,
whereas IL-10-depletion did not affect the phosphorylation level. Similarly, in mouse
macrophages, CM obtained from IL10-deficient peritoneal macrophages (GR-1-CMIL10–/–
) still induced STAT3 phosphorylation (Fig. 2.5B). We also used macrophages lacking
G-CSF receptor (G-CSFR–/–) to examine the role of G-CSF. Figure 2.5C shows that GR1-CM induced strong STAT3 Y705 phosphorylation in G-CSFR+/+ macrophages, but the
phosphorylation was completely absent in G-CSFR–/– macrophages. In addition, STAT3
Y705 phosphorylation was induced by hG-CSF at a concentration of 100 pg ml−1 and
maximally at 500 pg ml−1 (Fig. 2.5D). These concentrations were well correlated with the
suppression level of TNF production (Fig. 2.3D). Although both IL-10 and G-CSF
induces STAT3 Y705 phosphorylation, it was shown that G-CSF-induced STAT3
phosphorylation is mainly mediated through Janus kinase 2 (JAK2) and that the JAK2specific inhibitor AG490 significantly blocks G-CSF-induced STAT3 activation (41, 47).
On the other hand, IL-10-induced STAT3 phosphorylation is unaffected by AG490 (41,
48). GR-1-CM-induced phosphorylation of STAT3 Y705 was also completely blocked
by AG490 (Fig. 2.5E), which further supports the notion that G-CSF is the main factor
involved in the activation of STAT3.
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Figure 2.5: STAT3 Y705 phosphorylation by GR-1-CM is mainly mediated through
G-CSF. A. GR-1-CM prepared from THP-1 cells was incubated with neutralizing human
G-CSF (0.1 µg ml−1) or IL-10 (0.3 µg ml−1) antibodies for 1 h. Non-treated CM (CNT),
GR-1-CM or GR-1-CM with neutralizing antibodies were then exposed to fresh THP-1
cells for 30 min. B. BMDIM were treated with GR-1-CMwt or GR-1-CMIL10–/–, which
were prepared from C57BL/6 wild-type or C57BL/6IL10–/– primary macrophages
respectively. C. GR-1-CM prepared from BMDIM was exposed to G-CSFR+/+ or GCSFR–/– primary macrophages. D. THP-1 cells were treated with non-treated CM (CNT)
or GR-1-CM prepared from THP-1 cells or different concentrations of recombinant
human G-CSF. E. THP-1 cells were treated with GR-1-CM in the presence or absence of
JAK2 inhibitor AG490 (30 µM) pretreatment (30 min). STAT3 was analysed using
phospho-specific Western blot analysis. Results are representative of two independent
experiments.
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Figure 2.5
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Fig. 5. STAT3 Y705 phosphorylation by GR-1-CM is mainly mediated through G-CSF.
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B. BMDIM were treated with GR-1-CMwt or GR-1-CMIL10–/–, which were prepared from C57BL/6 wild-type or C57BL/6IL10–/– primary macrophages
respectively.
C. GR-1-CM prepared from BMDIM was exposed to G-CSFR+/+ or G-CSFR–/– primary macrophages.
D. THP-1 cells were treated with non-treated CM (CNT) or GR-1-CM prepared from THP-1 cells or different concentrations of recombinant human
G-CSF.
E. THP-1 cells were treated with GR-1-CM in the presence or absence of JAK2 inhibitor AG490 (30 µM) pretreatment (30 min). STAT3 was
analysed using phospho-specific Western blot analysis. Results are representative of two independent experiments.

STAT3 activation is required for the suppression of TNF
production by GR-1-CM
To examine whether STAT3 activation is required for GR1-CM-mediated inhibition of TNF production, we first
assessed the TNF suppressing effects of GR-1-CM in the
presence or absence of different chemical inhibitors for
JAKs and STAT3 in BMDIM. As shown in Fig. 6A, the
suppressive effects of GR-1-CM on TNF production was
almost completely abolished by membrane permeable
STAT3 inhibitor peptide (STAT3i) and JAK2 inhibitor
AG490, but not by JAK3 inhibitor, indicating that the GR1-CM inhibitory effect required JAK2-mediated STAT3
activation. We further examined whether the phosphorylation at Y705 is crucial for the GR-1-CM suppressive
effects using adenovirus-mediated overexpression of
Y705F-mutated dominant negative human STAT3
(hSTAT3-DN). Y705 phosphorylation was previously
shown to be necessary for dimerization formation and
transcription activation (Shuai et al., 1994). We infected
human monocytic THP-1 cells with either adenovirus

encoding hSTAT3-DN or empty adenovirus vector
(Ad-vector) as previously described by Williams et al.
(Williams et al., 2004). THP-1 cells infected with either Advector or DN-hSTAT3 induced TNF in response to E. coliSCS (Fig. 6B). GR-1-CM suppressed TNF production in
Ad-vector-infected cells, whereas in DN-hSTAT3-infected
cells TNF production was not suppressed by GR-1-CM.
These data indicate that STAT3 Y-705 phosphorylation is
required for the suppression of TNF production.
STAT3-mediated inhibition of JNK activation by GR-1-CM
is a key mechanism that suppresses TNF production in
E. coli-activated macrophages
It has been shown that bacterial components such as LPS
activate MAPKs, Akt (PKB) and NF-κB, which are key
signalling molecules for regulating production of TNF (van
den Blink et al., 2001; Ojaniemi et al., 2003). Therefore,
we examined whether GR-1-CM pretreatment modulates
activation of these signalling molecules using Western blot
analysis. As shown in Fig. 7A, GR-1-CM did not affect

© 2006 The Authors
Journal compilation © 2006 Blackwell Publishing Ltd, Cellular Microbiology, 8, 1958–1971
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2.3.6

STAT3 activation is required for the suppression of TNF
production by GR-1-CM

To examine whether STAT3 activation is required for GR-1-CM-mediated inhibition of
TNF production, we first assessed the TNF-suppressing effects of GR-1-CM in the
presence or absence of different chemical inhibitors for JAKs and STAT3 in BMDIM. As
shown in Fig. 2.6A, the suppressive effects of GR-1-CM on TNF production was almost
completely abolished by membrane permeable STAT3 inhibitor peptide (STAT3i) and
JAK2 inhibitor AG490, but not by JAK3 inhibitor, indicating that the GR-1-CM
inhibitory effect required JAK2-mediated STAT3 activation. We further examined
whether the phosphorylation at Y705 is crucial for the suppressive effects of GR-1-CM
using adenovirus-mediated overexpression of Y705F-mutated dominant negative human
STAT3 (hSTAT3-DN). Y705 phosphorylation was previously shown to be necessary for
dimer formation and transcription activation (49). We infected human monocytic THP-1
cells with either adenovirus encoding hSTAT3-DN or empty adenovirus vector (Advector) as previously described by Williams et al. (36). THP-1 cells infected with either
Ad-vector or DN-hSTAT3 produced TNF in response to E. coli-SCS (Fig. 2.6B). GR-1CM suppressed TNF production in Ad-vector-infected cells, whereas in DN-hSTAT3infected cells TNF production was not suppressed by GR-1-CM. These data indicate that
STAT3 Y-705 phosphorylation is required for the suppression of TNF production.
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Figure 2.6: STAT3 Y705 phosphorylation induced by G-CSF is required for the
GR-1-CM-induced

suppression

of

TNF

production

in

E.

coli-activated

macrophages. A. BMDIM were treated with none (CNT) or E. coli-SCS in the presence
of GR-1-CM with or without 30 min pretreatment of inhibitors for JAK2 (AG490; 30
µM), JAK3 (JAK3i; 100 µM) and STAT3 (ST3i; 0.5 mM). B. DN-hSTAT3 (Y705F) was
overexpressed using an adenoviral vector in human monocytic THP-1 cells. Top panel
shows overexpression of DN-hSTAT3 in DN-hSTAT3 adenovirus-transfected THP-1
cells. Endogenous STAT3 was almost undetectable in empty adenovirus-transfected cells
under the same Western blotting conditions. The adenovirus empty vector or DNhSTAT3-transfected THP-1 cells were treated with none (CNT), E. coli-SCS, E. coliSCS + GR-1-CM or GR-1-CM. Production of TNF was measured 9 h after treatment as
described in the legend to Fig. 2.1. Data are expressed as means + SD of three
independent experiments.
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2.3.7

STAT3-mediated inhibition of JNK activation by GR-1-CM is
a key mechanism that suppresses TNF production in E. coliactivated macrophages

It has been shown that bacterial components such as LPS activate MAPKs, Akt (PKB)
and NF-κB, which are key signalling molecules for regulating production of TNF (50,
51). Therefore, we examined whether GR-1-CM pretreatment modulates activation of
these signalling molecules using Western blot analysis. As shown in Fig. 2.7A, GR-1-CM
did not affect degradation of IκB-α nor activation of Akt, ERK1 and ERK2 by E. coliSCS. However, activation of p46- and p54-JNKs was completely blocked by GR-1-CM
in BMDIM. Similar results were detected in THP-1 cells (data not shown). To further
examine whether the JNK inhibition requires STAT3 Y705 phosphorylation, adenovirusmediated overexpression of human DN-hSTAT3 and the JAK2 inhibitor AG490 were
used in THP-1 cells. As shown in Fig. 2.7B, LPS-induced phosphorylation of JNK was
inhibited by GR-1-CM in THP-1 cells and adenoviral empty vector transfected THP-1
cells. The inhibition of JNK was completely reversed by AG490 (30 µM) and DNhSTAT3 overexpression (Fig. 2.7B). These data indicate that the inhibition of JNK
activation by GR-1-CM is mediated through STAT3 activation.
Although STAT3 activation is required for inhibition of LPS-induced JNK activation,
this does not necessarily indicate that JNK inhibition is involved in the suppression of
TNF production. To confirm the role of JNK inhibition in the suppression of TNF
production, we constitutively activated JNK using adenoviral overexpression of wild-type
human MAPK kinase 7 (MKK7), a JNK-specific upstream kinase (52), in THP-1 cells.
Figure 2.7C shows that overexpression of wild-type MKK7 constitutively induced JNK
activation and that this JNK activation was not affected by GR-1-CM treatment. We then
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measured whether suppression of TNF production by GR-1-CM was abolished in
MKK7-transfected cells. As shown in Fig. 2.7D, TNF production induced by LPS was
suppressed by GR- 1-CM in Ad-vector transfected cells but not in MKK7 overexpressing cells. These results suggest that inhibition of JNK is a crucial step for GR-1CM-mediated suppression of TNF production.
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Figure 2.7: Specific inhibition of JNKs by GR-1-CM is mediated through STAT3. A.
BMDIM were treated with none (CNT), E. coli-SCS with or without pretreatment (45
min) of GR-1-CM for the time indicated. GR-1-CM specifically inhibited tyrosine
phosphorylation of JNKs without apparent inhibition of other signalling molecules. B.
Human monocytic THP-1 cells were treated with none (CNT) or LPS (100 ng ml−1) with
or without pretreatment of GR-1-CM or GR-1- CM + AG490 (30 µM). Similarly, THP-1
cells transfected with adenovirus empty vector or DN-hSTAT3 (Y705F) were treated
with LPS with or without pretreatment of GR-1-CM for 30 min. Total cell lysates (35 µg
per lane) were analysed by Western blotting using phospho-specific or anti-peptide
antibodies against the indicated proteins. Results are representative of three independent
experiments. C and D. THP-1 cells were transfected with adenoviral empty vector or
wild-type MKK7. C. Activation of JNK was analysed using Western blots and
overexpression of MKK7 constitutively induced JNK phosphorylation. D. GR-1- CM
failed to suppress TNF production in LPS- activated cells overexpressing MKK7. Data
are expressed as means + SD of three independent experiments.
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2.3.8

Inhibition of JNKs by STAT3 requires de novo protein
synthesis

To examine whether inhibition of JNK activation by GR-1- CM requires transcriptional
activation of STAT3, we analysed JNK inhibition in GR-1-CM-exposed THP-1 cells
after pretreating cells with a translational inhibitor actinomycin D (20 µg ml−1) for 30
min. As shown in Fig. 2.8A, the inhibitory effect of GR-1-CM on JNK activation was
abolished by actinomycin D, indicating that de novo protein synthesis is required for the
JNK inhibition. To further investigate the role of STAT3, we tested whether
constitutively active STAT3α mimics the GR-1-CM effect on JNK activation and on
TNF production. Expression of constitutively active human STAT3α-C, which forms
homo-dimerization through cysteine–cysteine residues instead of phosphotyrosine–SH2
interactions (53), suppressed JNK activation induced by LPS (Fig. 2.8B). Production of
TNF induced by LPS was also diminished about 40% in THP-1 cells constitutively
expressing STAT3α-C (Fig. 2.8C). These results indicate that transcriptional activation of
STAT3 is required for the inhibition of JNK activation and subsequent TNF production
in GR-1-CM-treated macrophages.
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Figure 2.8: Inhibition of JNK by GR-1-CM requires STAT3α-mediated de novo
protein synthesis. A. THP-1 cells were treated with GR-1-CM for 45 min with or
without pretreatment with actinomycin D (20 µg ml−1) for 30 min, and then exposed to
none (CNT) or LPS (100 ng ml−1) for 30 min. B. THP-1 cells constitutively expressing
hSTAT3α-C were treated with LPS (100 ng ml−1) for 30 min in the presence or absence
of GR-1-CM pretreatment (45 min). Activation of p38 and JNKs was analysed by
phospho-specific Western blotting. Results are representative of two independent
experiments. C. Production of TNF in response to LPS (100 ng ml−1) in wild-type or
hSTAT3α-C-transfected THP-1 cells was analysed as described in the legend to Fig. 2.1.
Data are expressed as means + SD of three independent experiments.
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2.4 Discussion
Probiotics such as strains of lactobacilli have been recognized as health-beneficial
microorganisms attenuating inflammation in the intestine (3-7). In addition to local
immunomodulatory roles, recent studies have also shown that Lactobacillus can
modulate host inflammation away from the site of contact (8, 13) and systemic antiinflammatory effects can also be achieved through subcutaneous injection of probiotics
(16). Macrophages are present in almost all tissues and modulate immune responses
through releasing autocrine and paracrine factors. Under normal conditions, marked
numbers of mononuclear cells infiltrate into the colonic mucosa without inducing
inflammation (23). In susceptible individuals, the immunologic tolerance of resident or
newly infiltrated macrophages to intestinal microbes is lost and chronic inflammation
ensues (25-27, 54). Probiotics such as L. rhamnosus have been shown to suppress the
inflammatory responses in such conditions (3-8). In this study, we have shown that L.
rhamnosus GG and GR-1 are inefficient in inducing production of the pro-inflammatory
cytokine TNF in macrophages (Fig. 1A), but rather preferentially induce secretion of
anti-inflammatory cytokines such as IL-10 and G-CSF (Fig. 2.2). Suppression of immune
responses through inhibitory autocrine and paracrine factors is a common strategy of
some pathogens including mycobacteria and parasitic nematodes. Pathogenic strains of
Mycobacterium tuberculosis have been shown to induce IL-6 and inhibit the
inflammatory responses of macrophages (20). The IL-6 secreted by M. tuberculosisinfected macrophages inhibits the responses of uninfected adjacent macrophages to IFNγ. Parasitic nematodes including helminths and filarial nematodes have been shown to
drive the infected host to TH2 type responses through IL-10-dependent and independent
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paracrine routes, resulting in down-regulation of production of various inflammatory
cytokines such as TNF and IL-12 (18, 55-57). It is not yet known whether production of
anti-inflammatory cytokines is necessary for the in vivo anti-inflammatory effects of
Lactobacillus. Although IL-10 is a potent and well-studied anti-inflammatory cytokine
(39), studies in IL-10 knockout mice indicate that production of IL-10 is dispensable for
the anti-inflammatory effects of Lactobacillus (3, 6, 7, 22). This in vitro study showed
that IL-10 was not required for the suppression of TNF production in macrophages (Fig.
2.3). We have found that live GG and GR-1 or their SCS induced G-CSF production at a
range of 50–75 ng ml−1, concentrations that were high enough to potently suppress LPSinduced TNF production (Fig. 2.3D). The suppression of TNF production by GR-1 CM
was likely mediated through down-regulation of TNF mRNA expression (Fig. 2.1C) and
a paracrine effect of G-CSF, as G-CSFR–/– macrophages produced similar amounts of
TNF as wild-type cells (Fig. 2.3C). A previous study has shown that peak production of
TNF (3–4 h of post-treatment) precedes the production of G-CSF, which peaks at 10–24
h after LPS stimulation in THP-1 cells (58).
G-CSF is required for the differentiation of neutrophils in the bone marrow and at the
same time elicits potent anti-inflammatory effects in monocytes and in septic mice (40,
41, 59). Unlike IL-10, which has broader anti-inflammatory effects, G-CSF is unique in
that it suppresses production of pro-inflammatory cytokines while simultaneously
activating the antibacterial function of neutrophils (40). Therefore, suppression of
inflammation through induction of G-CSF by probiotics may be particularly important in
the intestine and urogenital tracts where antimicrobial activity has to be preserved.
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Seven different human G-CSF receptor isoforms have been described, which are
generated by alternative splicing; however, the physiologic roles of these isoforms and
the expression pattern on various cell types are still unknown (40). The dissociation
constant for G-CSF with its receptor has been measured at approximately 60–80 pM (60,
61). However, the biologic response is induced at a much lower concentration (halfmaximal at 3 pM ≈ 72 pg ml−1) (60), suggesting that only a low percentage of receptors
need to be occupied for relevant signal transduction to occur. In human peripheral
monocytes, inhibition of LPS-induced TNF production by G-CSF was detected at 10–500
ng ml−1 (41, 62). This study showed that hG-CSF induced STAT3 activation and
significantly inhibited LPS-induced TNF production at 300– 500 pg ml−1 range,
indicating that human monocytic THP-1 cells are more sensitive to G-CSF than
peripheral monocytes. In fact, a subset of monocytic cells was noted to bind G-CSF at
very low levels (60), whereas THP-1 cells were shown to express high-affinity G-CSF
receptors (63). It is not yet clear why E. coli-CM did not have TNF suppressing effects,
even though G-CSF was still present to about half the quantity induced by GG or GR-1
(Fig. 2.2). Unlike GG- or GR-1-stimulated BMDIM, E. coli harbouring LPS activates
TLR4 and potently produces type I interferons, granulocyte macrophage-CSF and IL-6.
Because these cytokines further enhance TNF production in activated macrophages (64,
65), it is possible that the lack of the suppressive effects in E. coli-CM may be due to the
counteracting enhancing effects induced by these factors.
G-CSF has been shown to attenuate LPS-induced release of TNF-α, which is mainly
mediated through activation of STAT3 (40). In human monocytes, G-CSF activates
STAT3 by inducing phosphorylation only at Y705 through activated JAK2, which is
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completely blocked by AG490 JAK2 inhibitor (41). IL-10 induces STAT3
phosphorylation at both Y705 and S725, which is not sensitive to AG490 JAK2 inhibitor
(41). ERK1 and ERK2 are also strongly activated by IL-10 but not by G-CSF. The
signalling mechanisms induced by GR-1-CM were very similar to those observed in GCSF-mediated pathways. GR-1- CM induced phosphorylation at Y705 but not at S725 of
STAT3 (Fig. 2.4A), Y705 phosphorylation was blocked by AG490 (Fig. 2.5E), and ERK
activation was not detected in GR-1-CM-treated cells (Fig. 2.4B). We further showed that
GR-1-CMIL10–/– still induced STAT3 Y705 phosphorylation (Fig. 2.5B), whereas the
phosphorylation was detected neither in macrophages treated with G-CSF-depleted GR1-CM (Fig. 2.5A) nor in G-CSFR–/– macrophages treated with GR-1-CM (Fig. 2.5C).
These data indicate that STAT3 activation by GR-1-CM was mainly mediated through GCSF. Interestingly, the intracellular protozoan T. gondii also elicits potent TNF
suppressing effects in macrophages, which is IL-10-independent but STAT3 activationdependent (66). Whether G- CSF also plays a role in T.gondii-mediated antiinflammatory effects has yet to be determined.
Activation of STAT3 was shown to be a key step for G-CSF-mediated suppression of
TNF production (41); however, the molecular mechanism remains to be unraveled. In
peripheral blood mononuclear cells (PBMC), G-CSF suppresses TNF production through
post-translational silencing (40) but in human monocytes, the level of TNF mRNA is also
diminished (41). STAT3 activation is also important for IL-10-induced anti-inflammatory
effects (67, 68); however, STAT3-independent anti-inflammatory effects were also
reported (36, 69). Inhibition of p38 MAPK activation by IL-10 in murine macrophages
was suggested as another mechanism for the suppression of TNF (70); however, in
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human monocytes and macrophages no such inhibition by IL-10 was detected (48, 71). In
this study, we showed that GR-1-CM potently and specifically inhibited JNK activation
induced by E. coli-SCS or LPS (Fig. 2.7A). The inhibition of JNK was dependent on
STAT3-Y705 phosphorylation, as overexpression of DN-STAT3 (Y705F) completely
reversed JNK inhibition (Fig. 2.7B). In addition, constitutive expression of a dominant
active form of STAT3α (STAT3α-C) abolished activation of JNK induced by LPS but
had no effects on p38 activation (Fig. 2.8B). Altogether, these data indicate that JNK
inhibition by GR-1-CM was mediated through STAT3 activation.
c-Jun-N-terminal kinase activation was shown to play a key role in TNF production (7274). Our data suggest that inhibition of JNK activation by GR-1-CM is a key step for
suppression of TNF production (Fig. 2.7C and D). How G-CSF-triggered STAT3
activation leads to JNK inhibition warrants further studies. Our present findings indicate
that the attenuation of JNK activation by GR-1-CM requires de novo protein synthesis, as
inhibition of mRNA translation by actinomycin D abrogated the JNK inhibitory effect of
GR-1-CM (Fig. 2.8A). Moreover, THP-1 cells constitutively expressing hSTAT3α-C
blocked JNK activation and subsequent production of TNF (Fig. 2.8B and C). Therefore,
our results indicate that the JNK inhibition by GR-1-CM or G-CSF was mediated through
STAT3-dependent transcriptional activity.
In summary, this study identified a novel mechanism for the suppression of TNF by L.
rhamnosus mediated through G-CSF paracrine effects in macrophages. G-CSF induced
STAT3 activation, which in turn prevented JNK activation and consequently resulted in
suppression of TNF production in LPS- or E. coli-activated macrophages.
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EXPERIMENTAL STATEMENT

98

3.1 HYPOTHESIS
Granulocyte-colony stimulating factor (G-CSF) has contrasting roles in the immune
system. On one hand, it can function as an inflammatory molecule by stimulating the
generation of neutrophils, which can subsequently contribute to inflammatory processes
(1). On the other hand, it has anti-inflammatory effects on other cells such as
macrophages and monocytes in vitro and in vivo (2, 3). Previously, it has been shown that
recombinant G-CSF administration can be beneficial in small clinical trials for IBD (4,
5), as well as in mouse models of colitis (6, 7). In addition, we have shown that probiotic
bacterial strains of Lactobacillus rhamnosus can potently stimulate the production of GCSF in macrophages, and that this G-CSF can block LPS-stimulated TNF production in
macrophages in a paracrine manner (8). However, little is known about the function of
endogenously produced G-CSF in the intestine, or the function of G-CSF in the action of
probiotics. Based on the previous studies described above, I hypothesized that
L.rhamnosus has anti-inflammatory effects on DCs through preferentially inducing GCSF in macrophages, and that G-CSF has an immunoregulatory role in the intestine.
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3.2 SPECIFIC AIMS
3.2.1

Specific Aim 1: Examining the effects of G-CSF on dendritic
cells.

DCs represent a key link connecting innate and adaptive immunity through the activation
of naïve T cells (9). The different stimuli received by DCs are thought to modulate their
functional capacity and ultimately alter the types of T cell immunity that are stimulated
(10). DCs play a vital role in the immunoregulation of the intestinal immune system
(11), and may be an important target for the anti-inflammatory effects of probiotics. In
the intestinal lamina propria, DCs are in close proximity to the large numbers of tissue
macrophages and other cells present as well as the commensal microbiota contained in
the lumen. In the case of probiotic treatment, these DCs may therefore be exposed not
only to signals received from the microbiota, such as products derived from the probiotic
bacteria, but also from cytokines produced by macrophages also responding to probiotic
stimulation.
In Chapter 4, we describe that G-CSF released by probiotic-treated macrophages can
inhibit the IL-12/23 p40 response of DCs. By using G-CSFR-/- DCs as well as G-CSF
neutralizing antibodies, we demonstrate that the high levels of G-CSF contained within
the media of probiotic-stimulated macrophages can inhibit the generation of IL-12/23 p40
induced in response to unidentified stimulatory components within the media, possibly
bacterial remnants. Consistent with this, recombinant G-CSF can inhibit the IL-12
response in DCs stimulated by LPS. These effects are in part mediated by the inhibition
of JNK activation by G-CSF. Finally, we show that GR-1 injected intraperitoneally in
mice produce high levels of G-CSF but not TNFα in the blood, and this GR-1-induced G-
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CSF had anti-inflammatory effects on splenic DCs, as observed by the reduced
expression of IL-12/23 p40 upon LPS stimulation ex vivo.

3.2.2

Specific Aim 2: Determining the G-CSF response of human
intestinal lamina propria mononuclear cells from IBD and
non-IBD afflicted individuals induced by L.rhamnosus GR-1.

To determine if the observed effects of G-CSF in the context of the response to probiotics
are relevant to the treatment of IBD, it is important to examine the response of
physiologically relevant cells to probiotics in terms of G-CSF production. The intestinal
lamina propria, lying just below the epithelial layer, contains a dense population of
immune cells, including numerous macrophages. As we had observed preferential
production of G-CSF in response to GR-1 in macrophages in vitro, we sought to
determine if GR-1 would be able to induce G-CSF production in lamina propria
mononuclear cells isolated from patients undergoing surgery for IBD or non-IBD
conditions (i.e. colon cancer). As inflamed regions of intestinal tissue are known to overproduce many different cytokines including G-CSF (12-16), we chose to focus on cells
isolated from non-inflamed regions of tissue to allow us to better examine the specific
responses to probiotics. As the normal intestinal tissues of non-diseased individuals are
very difficult to obtain, non-involved regions of tissue isolated from patients undergoing
intestinal resection for the treatment of colon cancer were obtained to use for comparison
with tissues of IBD-afflicted individuals.
As we will show in Chapter 5, we found that cells isolated from non-IBD individuals
spontaneously release very high levels of G-CSF; in contrast, spontaneous G-CSF release
by IBD-derived cells is greatly reduced. In addition, G-CSF production in response to
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bacterial stimulation is altered in IBD. While non-IBD-derived cells show higher
production of G-CSF in response to GR-1 than E. coli, cells isolated from IBD patients
produce more G-CSF in response to E. coli than GR-1. Overall, GR-1 induces increased
levels of G-CSF in about half of the patients tested, reminiscent of the overall response
rate to probiotic treatment in clinical trials. Furthermore, we go on to show normal mouse
intestinal tissue also expresses high levels of G-CSF, that the intestinal tissues of GCSFR-/- mice show higher basal levels of the inflammatory cytokines TNFα, IL-12, and
IL-23, and that G-CSF can effectively inhibit IL-23 expression induced by LPS in human
peripheral blood monocytes. These results highlight that IBD is associated with an altered
response to bacterial stimulation, which may result in reduced production of antiinflammatory cytokines such as G-CSF.

3.2.3

Specific Aim 3: Examining the role of endogenous G-CSF in
intestinal inflammation using a mouse model of colitis and
the basis for the intestinal expression of G-CSF.

In Aims 1 and 2, we illustrate the relevance of G-CSF to the effects of probiotics and
human inflammatory bowel disease. Although in Aim 2 we demonstrate that G-CSFR-/intestinal tissue expressed higher levels of inflammatory cytokines, in our hands, these
mice have not been observed to succumb to the spontaneous development of colitis,
suggesting that this defect is not enough to cause colitis or to overcome compensation by
other anti-inflammatory mechanisms. To determine what modulating role endogenous GCSF may play when tissue homeostasis is perturbed, we will utilize a well-studied model
of intestinal inflammation induced by treatment with dextran sulfate sodium (DSS). DSS
is believed to act by causing epithelial cell death in the intestine (17), and massive
inflammation ensues as the underlying immune populations become exposed to high
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concentrations of luminal bacteria. In addition, we will determine why G-CSF is so
highly expressed in the isolated non-inflamed intestinal tissue, using knockout and germfree mouse models.
In Chapter 6, we describe that G-CSFR-/- mice treated with 1.5% DSS show enhanced
intestinal tissue damage and the presence of a pseudomembranous structure infected with
bacteria, not observed in DSS-treated G-CSFR+/+ or +/-. The intestinal tissue of DSStreated G-CSFR-/- mice also show enhanced IL-17 production, and isolated intestinal
tissue of non-treated G-CSFR-/- mice exhibit enhanced cell death when subjected to
tissue disruption ex vivo. These results suggest that G-CSF can play an anti-inflammatory
and/or pro-survival role that may be beneficial in colitis, and that G-CSFR-/- mice are
more prone to pseudomembrane and secondary infection development after DSS
treatment. This process is likely to be related to reduced neutrophil function in G-CSFR/-, as while abundant neutrophils are found in the inflamed tissue of DSS-treated GCSFR-/- mice, these cells exhibit a lower staining intensity of myeloperoxidase, which is
important for the bactericidal activity of neutrophils. Finally, Chapter 6 describes that the
high levels of G-CSF production seen in intestinal tissue explants is stimulated via a
MyD88-dependent, but intestinal microbiota-independent route. These results indicate
that the observed G-CSF production is likely to be a response to tissue injury, and that GCSF may be induced by IL-1β or endogenous TLR ligands released from the damaged
tissue.
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Chapter 4

4

⁋

THE ANTI-INFLAMMATORY ROLE OF
GRANULOCYTE COLONY-STIMULATING FACTOR
IN MACROPHAGE-DENDRITIC CELL CROSSTALK
AFTER LACTOBACILLUS RHAMNOSUS GR-1
EXPOSURE⁋

The material contained in this chapter has been published as: Martins, A. J., Spanton, S.,

Sheikh, H. I., and Kim, S. O. (2011) The anti-inflammatory role of granulocyte colonystimulating factor in macrophage-dendritic cell cross-talk after Lactobacillus rhamnosus
GR-1 exposure. J. Leukocyte Biol. (Online ahead of print, doi:10.1189/jlb.0810445)
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4.1 INTRODUCTION
Probiotics are defined as live micro-organisms that confer beneficial heath effects on the
host

when

administered

in

ftp://ftp.fao.org/es/esn/food/wgreport2.pdf).

adequate
Such

doses

beneficial

(1)(FAO/WHO,
effects

may

vary

considerably depending on the probiotic organism examined. These effects may include
exclusion of harmful microbes by occupying an ecological niche, producing antimicrobial compounds, stimulating the host’s anti-microbial immune defenses, or
modulating inflammatory responses (2, 3). The immunomodulatory effects of probiotic
bacterial strains have garnered much interest for their application in treating
inflammatory diseases such as arthritis and inflammatory bowel diseases (IBD). Different
strains are likely to induce varied immune responses, such as the stimulation of distinct
cytokine profiles, which can then have anti-microbial or anti-inflammatory effects on the
host immune system (4). Anti-inflammatory effects may be mediated through the release
of cytokines such as IL-10 or TGF-β, or the stimulation of Treg responses (5). These
effects could be harnessed therapeutically to manipulate immune responses; however,
detailed knowledge of the effects of specific strains on immune cells is needed to
precisely predict the effects of these strains on the host (6).
Dendritic cells (DCs) are key antigen presenting cells, capable of acquiring antigens in
the periphery and migrating to the lymph nodes, where they can present antigenic
peptides to activate naïve T cells. The activation of DCs by signals such as bacterial
products or cytokines is thought to affect the type of T cell responses they initiate. The
interaction of probiotic bacteria with dendritic cells may be part of their observed
immunomodulatory effects; therefore, investigation of these interactions has been
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undertaken, with varying results (5, 7-10). In addition to direct effects on DCs, the local
cytokine milieu produced by probiotic bacteria-exposed macrophages (MФs), containing
factors such as IL-12, IL-4, IL-6 and IL-23, or IL-10, may affect the activation of DCs
and in turn skew T cell responses towards Th1-, Th2-, Th17-, or Treg, respectively.
G-CSF is a pleiotropic cytokine best known for its role in promoting the production and
function of neutrophils (11). In addition, systemic anti-inflammatory effects of this
cytokine have been observed, which are thought to be mediated through modulation of T
cells and DCs (12). As recombinant G-CSF is approved as a therapeutic agent for several
disease states, such as immune reconstitution after chemotherapy-induced neutropenia
and the mobilization of bone marrow stem cells into the blood prior to harvesting for
stem cell transplant, valuable information regarding in vivo responses to this cytokine has
been attained (13).
Previously, we have shown that the probiotic strain Lactobacillus rhamnosus GR-1 (GR1) elicits the release of G-CSF from MФs, and that the paracrine effects of G-CSF on
neighboring MФs suppresses subsequent inflammatory reactions (14). GR-1 treatment
increased G-CSF expression in isolated human intestinal lamina propria cells from a
subset of patients tested, and lower G-CSF responses were observed in cells from those
afflicted with IBD (15). Previous studies by others have shown that systemic
administration of recombinant G-CSF has beneficial effects on IBD (16, 17), implying
that G-CSF may play a regulatory role in the intestine, perhaps through antiinflammatory effects on key immune cells such as MФs and DCs. To further understand
the role G-CSF may play in the immunoregulatory effects of probiotics, we examined the
effects of Lactobacillus-induced G-CSF on DCs. We found that G-CSF produced by L.
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rhamnosus GR-1 (GR-1)-exposed MФs has anti-inflammatory effects on DCs in terms of
modulating IL-12/23 p40 production, at least in part through inhibiting the
phosphorylation of c-jun N-terminal kinase (JNK). Since MФs are highly populated in
the lamina propria of the intestine (18), MФs-derived cytokines could influence the
function of DCs that have transiently migrated to the lamina propria, where they acquire
antigen for presentation locally or in the lymph nodes (19). Therefore, these results give
new insight into the role of G-CSF and MФ-DC crosstalk in the immunomodulatory
effects of probiotic strain L.rhamnosus GR-1.
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4.2 MATERIALS AND METHODS
4.2.1

Mice

C57BL/6 and Balb/c mice were purchased from Jackson Laboratories (Bar Harbor, ME).
G-CSFR-/- mice (20), backcrossed onto the C57BL/6 background, were originally
obtained from Daniel C. Link (Washington University Medical School, St. Louis, MO),
and maintained in the Animal Care and Veterinary Services facility at The University of
Western Ontario under conventional conditions. C57BL/6 and G-CSFR-/- were crossed,
and G-CSFR+/- offspring were then crossed to generate G-CSFR+/+ and -/- littermates.
Matched pairs of littermates were used whenever possible. Male and female mice aged 4
to 10 weeks were used in all experimental procedures. All experimental protocols were
approved by the University of Western Ontario Animal Use Subcommittee, which
follows the regulations of the Animals for Research Act (Ontario) and the Canadian
Council on Animal Care.

4.2.2

Cell lines, Bacteria, and Reagents

Mouse bone marrow-derived immortalized MФs from C57BL/6 mice were originally
obtained from Dr. Bharat Aggarwal (14, 21) (MD Anderson Cancer Center, University of
Texas, Houston, TX) and grown in RPMI media (Sigma-Aldrich Canada, Oakville,
Ontario) supplemented with 10% fetal bovine serum (Sigma-Aldrich), 1 mM nonessential amino acids (Sigma-Aldrich), 1 mM sodium pyruvate (Sigma-Aldrich), 100
U/mL penicillin and 0.1 mg/mL streptomycin (Sigma-Aldrich), (referred to as complete
(C)-RPMI) and incubated at 37°C with 5% CO2. Lactobacillus rhamnosus GR-1 from our
strain collection was grown for 48 hours anaerobically in de Man, Rogosa, and Sharpe
media (BD-Canada, Mississauga, Ontario). Escherichia coli GR-12, originally isolated
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from a patient with pyelonephritis (22), was grown overnight in Luria-Bertani broth
under aerobic conditions. Bacterial cells were centrifuged at 4,000g for 5 minutes and
resuspended in sterile phosphate-buffered saline. This was repeated three times, and
bacteria were finally resuspended in phosphate-buffered saline to an OD reading of 1.0 at
600 nm, representing approximately 109 cfu/mL. LPS derived from E. coli O111:B4 was
purchased from List Biological Laboratories (Campbell, CA). LTA, derived from
S.aureus, was obtained from Sigma-Aldrich. Polymyxin B was obtained from Sigma.
Recombinant mouse G-CSF and IFNγ was purchased from R&D Systems (Minneapolis,
MN). Anti-CD3 antibody for the activation of T cells was obtained from eBioscience
(San Diego, CA).

4.2.3

Generation of bone marrow-derived DCs

For the generation of DCs, bone marrow was flushed out of femurs and tibia obtained
from G-CSFR+/+ and G-CSFR-/- mice (age 4-10 weeks) using a fine needle and PBS.
Bone marrow cells were incubated in C-RPMI supplemented with 55 µM 2mecaptoethanol, 10 mM HEPES, GM-CSF and IL-4 (10 ng/mL of each, Peprotech) to
stimulate the differentiation of dendritic cells. Culture media was replaced with fresh
media containing cytokines 2 or 3 days after initiation of the culture, and cells were used
in experiments 5 to 7 days after culture initiation.

4.2.4

Generation of Mɸ conditioned media

Conditioned media (CM) of bacteria-treated MФs were prepared as described previously
(14). Bone marrow-derived immortalized MФs from C57BL/6 mice were plated at a
concentration of 1 million cells per mL in antibiotic free C-RPMI. MФs were treated with
20 µL/mL of a bacterial suspension with an OD at 600 nm of 1, representing
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approximately 20 cfu per MФ, for 1-4 hours at 37 °C. Cells were then washed
extensively with fresh media, and incubated overnight (18 hr) with fresh supplemented
RPMI containing penicillin and streptomycin (C-RPMI). The media was then filtered
though a 0.2 µm sterile filter and frozen at -20 until use. To neutralize G-CSF activity
within the CM, CM was treated for 1 hr with 1 µg/mL anti-G-CSF (Cedarlane,
Burlington, Ontario) at 37°C before addition of CM to the DC culture. CM was mixed in
a 1:1 ratio with fresh media supplemented with growth factors for DC culture (see
above).

4.2.5

Adenovirus-mediated over-expression of MEK7

MEK7 adenovirus was obtained from J. Han (The Scripps Research Institute, La Jolla,
CA). For transient overexpression of MEK7, dendritic cells were infected with MEK7- or
empty-adenovirus at a multiplicity of infection of 100 in serum-free media for one hour,
then washed and incubated overnight in C-RPMI before use in experiments the next day.

4.2.6

Surface, Intracellular Staining and Flow Cytometry

For the analysis of CD80 and CD86 expression, DCs were stimulated overnight,
harvested and stained for 20 minutes on ice before reading on a FACSCalibur flow
cytometer (BD, Franklin Lakes, NJ). For the analysis of intracellular expression of IL12/23 p40, cells were stimulated for 6-18 hours as stated in the figure legends, the final 4
hours in the presence of 10 µg/mL brefeldin A (Biolegend, San Diego, CA), and then
fixed with 1% formaldehyde for ten minutes before fluorochrome-linked antibody
staining for 20 minutes in PBS containing 0.1% saponin and 5% FBS. Data acquisition
and analysis was performed using Cellquest (BD). Additional data analysis was
performed using FlowJo (Treestar, Ashland, OR). Fluorochrome-linked antibodies used
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for flow cytometry were obtained from eBioscience (San Diego, CA).

4.2.7

Cytokine Determination by ELISA

IL-12 was measured in cell culture supernatants using a p70-specific ELISA from R&D
Systems. G-CSF was measured using an ELISA from R&D Systems. IFNγ, IL-17, IL-23
(anti-p19 capture, anti-p40 detection), TGF-β, TNFα, GM-CSF, and IL-6 were measured
using ELISA kits from eBioscience. Standard curves were generated using recombinant
proteins provided by the manufacturer. For measurement of cytokine levels in mouse
serum, blood was obtained by the saphenous vein puncture method, and allowed to clot
prior to centrifugation and serum removal.

4.2.8

Quantitative Real-time PCR

Total RNA was prepared using Trizol reagent (Invitrogen Canada, Burlington, Ontario)
and 1 µg of RNA was reverse transcribed into cDNA using Oligo-dT priming and MMuLV-reverse transcriptase (NEB Biosciences, Pickering, Ontario). Gene expression
was then quantified using a Rotor-gene 3000 (Corbett Life Science, Concorde, NSW
Australia) and EXPRESS Sybr GreenER qPCR mix (Invitrogen). Expression levels were
quantified using the two-standard curve method with gapdh as a normalizer. Primer
sequences used were: gapdh 5′-GCATTGTGGAAGGGCTCATG-3′ (forward), 5′TTGCTGTTGAAGTCGCAGGAG-3′ (reverse), il-12b (the p40 subunit of IL-12) 5′AGTCCCTTTGGTCCAGTGTG-3′ (forward), 5′-AGCAGTAGCAGTTCCCCTGA-3′
(reverse). Primers were obtained from Sigma-Aldrich.

4.2.9

Western Blots

Total cell lysates were prepared using ice cold lysis buffer containing 20 mM MOPS, 15
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mM EGTA, 2 mM EDTA, 1 mM Na3VO4, 1 mM dithiothreitol, 75 mM βglycerophosphate, 0.1 mM phenylmethylsulphonyl fluoride, 1 µg/mL aprotinin, 10
µg/mL pepstatin A, 1 µg/mL leupeptin and 1% Triton X-100. After incubation in lysis
buffer on ice for 5 minutes, lysates were centrifuged for 15 minutes at 17,468g to remove
cell debris. SDS-PAGE loading buffer was then added to the cleared lysates (final
concentrations: 12.5% glycerol, 31.25 mM Tris-HCl, 1% SDS, 0.02% Bromophenol
Blue, and 1.25% β-mercaptoethanol). Samples were then boiled at 100°C for 5 minutes
before resolving on SDS-PAGE gels using Mini-Protean 3 apparatus (Bio-Rad,
Mississauga, Ontario, Canada). Transfer to nitrocellulose membranes was performed
using a Transblot SD semi-dry transfer system (Bio-Rad) at constant 18 volts for 1 hour.
Membranes were blocked for 30 minutes using 5% w/v skim milk before incubation with
primary antibodies. Staining was visualized using an enhanced chemiluminescence
detection system (Pierce Biosciences (Fisher Canada), Nepean, Ontario). Band intensity
quantification was performed using ImageJ (Rasband, W.S., ImageJ, U. S. National
Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2009),
normalized to loading controls (β-actin or total protein of interest). Antibodies used for
western blotting were obtained from Cell Signaling Technology (NEB Biosciences,
Pickering, Ontario).

4.2.10

Cytometric bead array analysis of phoshorylated JNK and
p38

Phosphorylated JNK and p38 were measured in cell lysates using the BD Cytometric
Bead Array (BD) according to the manufacturer’s instructions, with the following
modification: cells were lysed using the lysis buffer listed in the “Western blots” section
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above, prior to addition of the manufacturer’s denaturation buffer and boiling at 100°C
for 5 minutes. Quantification was carried out on a BD FACSCalibur. Units of
phosphorylated proteins were expressed relative to total protein measured by Bradford
Assay (Bio-rad).

4.2.11

In vivo GR-1 treatment and Spleen Cell Isolation

Mice were injected intraperitoneally (i.p.) with approximately 107 cfu of GR-1 suspended
in PBS 24 hours prior to spleen harvest. Mice were euthanized by CO2 asphyxiation.
Spleens were harvested and disrupted by gently forcing through a 40µm filter into PBS.
Red blood cells were lysed by incubating spleen cells in ammonium-chloride potassium
(ACK) lysis buffer (BioWhittaker, VWR International, Mississauga, Ontario) for 1
minute, followed by washing in C-RPMI. Cells were plated in C-RPMI and incubated at
37°C with 5% CO2. Splenic DCs were enriched by adherence to plastic culture dishes,
followed by DC specific analysis by gating on CD11c or CD80+ populations. Nonadherent cells were used in T cell stimulation assays.

4.2.12

Statistics and graphing

Statistical analysis was carried out using Prism 5.0c for Mac OS X (Graphpad Software,
La Jolla, CA). Two tailed t-tests and one-way ANOVA with Student Newman-Keuls
post-test was performed as described in the figure legends. Pooled results of several
independent experiments were used in all statistical analysis.
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4.3 RESULTS
4.3.1

Probiotic Lactobacillus strains induce a distinct cytokine
response in macrophages.

Previously, we have shown that MФs produce high levels of G-CSF and IL-10 but lower
levels of TNFα in response to Lactobacillus rhamnosus strains GR-1 (GR-1) in
comparison to E. coli GR-12, and that G-CSF induced by GR-1 has paracrine antiinflammatory effects in MФs (14). We further examined the production of other
cytokines in response to E. coli GR-12 and GR-1. The production of IL-6, IL-12 and
GM-CSF was lower in GR-1-exposed than E. coli GR-12-exposed MФs (Fig. 4.1).
However, the production of TGF-β was slightly higher in GR-1-exposed than E. coli GR12-exposed MФs. Together with our previous study in which G-CSF induced by GR-1
was detected at up to 50 ng/mL, these data show GR-1-treated MФs preferentially
produce remarkably high levels of G-CSF among several cytokines examined, and a
skewed cytokine profile towards anti-inflammatory cytokines such as G-CSF, IL-10, and
TGF-β.
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Figure 4.1: Live Lactobacillus strains preferentially induce high levels of antiinflammatory cytokine production in MФs. Cytokines produced by MФ were
measured by ELISA in the culture media 24 hours after stimulation. L. rhamnosus GR-1
treatment induced lower levels of IL-6, IL-12, and GM-CSF compared to E. coli GR-12,
but higher levels of TGF-β (B). Data representative of at least three experiments.
Mean+SEM shown. CNT = non-treated MФs.
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4.3.2

Cytokines released by GR-1-treated MФs do not induce
inflammatory responses in DCs.

The milieu of cytokines produced by MФs exposed to different bacteria could affect DC
activation. To examine how cytokines released by GR1-exposed MФs influence DC
activation, DCs were treated with conditioned cell culture media (CM) prepared from
either non-treated (CNT CM), GR-1 (GR-1 CM), or E. coli GR-12 (E. coli CM)-treated
MФs, in a 1:1 ratio with fresh culture media. E. coli CM enhanced intracellular
expression of the shared p40 subunit of IL-12 and IL-23 (IL-12/23 p40) (~29% of cells,
vs. ~11% in control; Fig. 4.2A; p<0.01; see Fig. 4.2D for representative histograms). To
determine if the increased response to the E. coli CM was due to the presence of residual
bacterial components in the media, E. coli CM was pre-treated with Polymyxin B, which
neutralizes the stimulatory effects of Gram-negative bacterial cell wall component
lipopolysaccharide (LPS). As shown in Table 4.1, Polymyxin B (Poly. B, 10 µg/mL)
almost completely blocked expression IL-12/23 p40 stimulatory capacity of E. coli spent
bacterial culture supernatant, verifying the effectiveness of polymyxin B to neutralize the
stimulatory capacity of E. coli-derived LPS that could be expected to be present in the E.
coli-CM. Polymyxin B decreased the IL-12/23 p40 response induced by E. coli CM to
comparable levels as those induced by CNT CM (Fig. 4.2A), suggesting that the
stimulatory effect of E. coli CM on DCs, over and above that of CNT CM itself, is
largely due to residual LPS from the E. coli. In contrast, E. coli CM-induced expression
of the co-stimulatory markers CD80 (Fig. 4.2B) and CD86 (Fig. 4.2C) was not blocked
by Polymyxin B, while the effect of E. coli spent bacterial culture supernatant was
blocked more than 50% (Table 4.1), suggesting LPS-independent stimulation of their
expression by E. coli CM. GR-1 CM failed to significantly induce IL-12/23 p40, CD80,
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or CD86 expression (Fig. 4.2). Also, unlike E. coli CM-treated DCs, GR-1 CM-treated
DCs did not induce T cell proliferation in a mixed lymphocyte reaction relative to CNT
CM (Fig. 4.3A), nor did they induce IFNγ and IL-17 production in syngeneic T cells
stimulated with anti-CD3 (Supplemental Fig. 4.3B & C). Overall, these results
demonstrated that GR-1 CM does not induce DC activation, while E. coli CM induces
activation through LPS-dependent and independent routes.
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Figure 4.2: Conditioned media (CM) of Lactobacillus rhamnosus GR-1 treated MФs
(GR-1 CM) does not induce an inflammatory phenotype in dendritic cells, while CM
of E. coli treated MФs (E. coli CM) induces high IL-12/23 p40 due to residual LPS
and increases co-stimulatory marker levels independent of residual LPS. Bone
marrow-derived DCs were treated overnight with CM in a 1:1 ratio with fresh media.
Intracellular levels of IL-12/23p40 (A) and surface expression of co-stimulatory
molecules CD80 (B) and CD86 (C) were measured by flow cytometry. GR-1 CM showed
no significant induction of these molecules relative to non-treated MФ CM (CNT CM),
while E. coli CM highly stimulated IL-12/23 p40 production and costimulatory molecule
expression. The stimulatory effects of E. coli CM on IL-12/23 p40, but not CD80 or
CD86, was LPS-dependent, as shown by the neutralization of LPS in the CM by
Polymyxin B (Poly. B, 10 µg/mL; also see Poly. B control experiments in Table 4.1). Bar
graphs show mean+SEM of pooled data from at least three independent experiments.
Representative histograms are shown for IL-12/23 p40 (D), CD80 (E), and CD86 (F).
*p<0.05, **p<0.01, ***p<0.001, paired one way ANOVA followed by Student NewmanKeuls post hoc test. CNT = non-treated DCs.
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Table 4.1: Verification of the activity of Polymyxin B
Analyte (% positive by flow cytometry)

Treatment

IL-12/23 p40

CD80

CD86

Control

8.3%

25.7%

28.1%

E. coli SCS

50.3%

52.1%

54.8%

E. coli SCS + Polymyxin B

14.9%

34.1%

37.9%

LPS

17.5%

48.6%

49.9%

LPS+ Polymyxin B

7.6%

27.2%

30.1%
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Figure 4.3: GR-1 CM treatment does not enhance T-cell stimulatory capacity of
DCs. CFSE-labeled spleen cells of Balb/c mice were used in a mixed lymphocyte
reaction with CNT CM and GR-1 CM-exposed DCs (C57BL/6 background) showed low
levels of proliferation of CD3+ and CD4+ double-positive T cells, while E. coli CM
treated DCs induced high levels of proliferation after 5 days of stimulation (A). E. coli
CM treated DCs induce higher levels of IFNγ (B) and IL-17 (C) in anti-CD3 (0.1 µg/mL)
stimulated syngeneic T cells 24 hours after stimulation than GR-1 CM treated DCs.
Representative of two independent experiments. **p<0.01, ***p<0.001, one way
ANOVA followed by Student Newman-Keuls post test. Data shown as mean+SEM.
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4.3.3

Live GR-1 weakly induces IL-12/23 p40 production in DCs
relative to E. coli GR-12.

As DCs appeared to be responding to residual bacterial products in the CM, we examined
the direct effect of live GR-1 and E. coli GR-12 on bone marrow-derived DCs in vitro.
Unlike live E. coli GR-12, which induced high levels of intracellular IL-12/23 p40
production, live GR-1 weakly induced production of the cytokine in DCs (Fig. 4.4).
These results indicate that while live GR-1 is capable of directly stimulating IL12/23p40, it is less stimulatory than live E. coli.
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Figure 4.4: Live GR-1 weakly induces IL-12/23 p40 expression in DCs. Bone-marrow
derived DCs were treated with 20 CFU of the indicated bacteria for 18 hours, the final 6
hours in the presence of brefeldin A. E. coli-treated cells show a large increase in
intracellular IL-12/23 p40 expression measured by flow cytometry, while in GR-1 treated
cells, IL-12/23 p40 is induced to lower levels. Representative of three independent
experiments.
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Figure 4.4
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4.3.4

G-CSF inhibits IL-12/23 p40 production in DCs in the context
of GR-1 CM.

Since the induction of IL-12/23 p40 by E. coli CM was dependent upon residual bacterial
LPS present in the CM, residual GR-1 bacterial cell products could similarly be present
in the GR-1 CM. However, while live GR-1 is able to at least weakly induce IL-12/23
p40 production in DCs (Fig. 4.4), GR-1 CM failed to induce any production of IL-12/23
p40 relative to CNT CM. This could be due to the lack of a sufficient concentration of
stimulatory components, or the inhibition of the IL-12/23 p40 response by an antiinflammatory cytokine(s) present in the GR-1 CM. To test if GR-1 CM contains an active
component that could inhibit inflammatory cytokine production, IL-12 secretion
stimulated by LPS was measured with or without pre-treatment of DCs with GR-1 CM.
Consistent with previous reports showing that the stimulation of IL-12 release requires
IFNγ in addition to LPS (23), LPS alone did not induce secretion of IL-12 from DCs,
despite high induction of mRNA and intracellular protein levels (data not shown);
therefore, LPS (0.1 µg/mL) plus IFNγ (1000U/mL) was used to induce IL-12 secretion.
GR-1 CM inhibited IL-12 secretion from LPS+IFNγ-treated DCs (Fig. 4.5A), indicating
the presence of an anti-inflammatory component. Since GR-1-exposed MФs secreted
large amounts of G-CSF (14), we examined the role of G-CSF in the inhibition of IL12/23 using G-CSF-neutralizing antibodies as well as DCs generated from G-CSFR-/mouse bone-marrow. G-CSFR-/- bone marrow cells differentiated into CD11c+ DCs to a
similar percentage as wild-type (G-CSFR+/+) cells, albeit at lower total numbers (Fig.
4.6A, 4.6B, and data not shown). G-CSFR-/- CD11c+ cells also showed similar
expression of CD80 and CD86 (Figure 4.6C). G-CSFR-/- DCs showed enhanced IL12/23 p40 production when treated with GR-1 CM alone (Fig. 4.5B, p<0.01), suggesting
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that G-CSF within the GR-1 CM was able to suppress the IL-12/23 p40 production in
response to a stimulatory component, possibly a GR-1-derived product present in the GR1 CM. To further confirm the role of G-CSF, G-CSF in the GR-1 CM was neutralized
using anti-G-CSF antibodies. GR-1 CM pre-treated with neutralizing anti-G-CSF
antibodies caused a slight but significant increase of IL-12/23p40 expression in wild-type
DCs (Fig. 4.5C, p<0.05). The minimal effect, relative to the enhanced IL-12/23 p40
production observed in G-CSFR-/- DCs, was possibly due to an incomplete neutralization
of the high levels of G-CSF present in the CM. To further examine the inhibitory effects
of G-CSF on DC activation, DCs were treated with LPS (100 ng/mL) with or without a
45 min pretreatment with recombinant mouse G-CSF (50 ng/mL). LPS-induced
expression of il12b (encoding the p40 subunit of IL-12) at the mRNA level was reduced
by ~50% after G-CSF pretreatment (Fig. 4.5D, p<0.05). Recombinant G-CSF also
inhibited IFNγ+LPS-induced IL-12 secretion by ~30% (Fig. 4.5E, p<0.01). In contrast to
the effects of G-CSF on IL-12 expression, recombinant G-CSF did not inhibit LPSinduced CD80 or CD86 expression (Fig. 4.5F). Together, these results show that G-CSF
produced by GR-1 treated MФs is capable of inhibiting the IL-12/23 response of DCs.
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Figure 4.5: G-CSF inhibits IL-12/23 p40 production in DCs. DCs were pretreated 15
minutes with GR-1 CM in a 1:1 ratio with fresh media, then stimulated with LPS (100
ng/mL) and IFNγ (1000 U/mL), and IL-12 release into the media was measured 24 hours
later by ELISA. GR-1 CM inhibits LPS-induced IL-12 release (A). DCs were stimulated
for 18 hours with CM, the final 6 hours in the presence of brefeldin A. Intracellular IL12/23 p40 production was measured by flow cytometry. G-CSFR-/- DCs produce
significantly higher levels of IL-12/23 p40 after GR-1 CM stimulation than wild-type
DCs (B). Antibody-mediated neutralization of G-CSF within the GR-1 CM, by
incubation of anti-GCSF (1 µg/mL) with GR-1 CM for 1 hr prior to the addition of CM to
the DC culture, also enhanced IL-12/23 p40 stimulation (C). DCs were pre-treated for 45
minutes with recombinant G-CSF (50 ng/mL), and then treated with LPS (0.1 µg/mL).
IL-12 mRNA was measured by qPCR. Recombinant G-CSF inhibits il12b (p40 subunit
of IL-12) mRNA transcription as measured by real-time qPCR, 6 hours after treatment
(D). Data is shown relative to the positive control (LPS alone), and normalized to gapdh.
No il12b expression was detected in non-treated cells. IL-12 protein (p70) was measured
by ELISA in the culture supernatant of LPS (0.1 µg/mL)+IFNγ (1000 U/mL) treated DCs
after 18 hours of stimulation. Recombinant G-CSF inhibits IL-12 secretion (E).
Recombinant G-CSF does not inhibit LPS-induced upregulation of CD80 or CD86,
measured by flow cytometry 24 hours after LPS treatment (F). *p<0.05, **p<0.01,
unpaired t-test (B) or paired t-test (C-E), where samples from the same experiment are
paired. Representative data of two independent experiments (A), or pooled data of at least
three independent experiments (B-E). Data shown as mean+SEM.
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Figure 4.5
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Figure 4.6: Comparison of G-CSFR+/+ and -/- bone marrow-derived DCs. Bone
marrow DC cultures on day 5 of differentiation showed similar percentages of CD11c
positive cells (A (representative dot plots), B (pooled data of multiple experiments)) and
CD80 and CD86 expression (C) measured by flow cytometry. Representative of at least
three experiments. Mean+SEM shown.
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